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Abstract: 
Asymptomatic arrhythmias are frequently encountered in clinical practice. Although studies 
specifically dedicated to these asymptomatic arrhythmias are lacking, many arrhythmias still 
require proper diagnostic and prognostic evaluation and treatment to avoid severe 
consequences, such as stroke or systemic emboli, heart failure or sudden cardiac death. The 
present document reviews the evidence, where available, and attempts to reach a consensus, 
where evidence is insufficient or conflicting.  
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I. Introduction  
An individual´s awareness of having an abnormal heart rhythm can be highly variable. While 
many patients are acutely aware of even a minor heart rhythm irregularity others may be 
unaware to episodes of rapid tachyarrhythmias.  
Palpitations are the most common symptom reported by patients with cardiac arrhythmias of 
various types and duration. The term “palpitations” refers to a subjective perception of an 
abnormal cardiac activity, described by patients as an uncomfortable sensation of pulsation or 
motion in the chest and/or adjacent areas (1). Some report other symptoms, in association with 
a documented cardiac arrhythmia, such as fatigue, shortness of breath, dyspnoea, chest 
discomfort, dizziness or syncope. These symptoms are sometimes referred to as “atypical 
presentations” of a symptomatic arrhythmia (2).  
 
On the other hand, some individuals with cardiac arrhythmias can be asymptomatic. Arrhythmias 
that may in certain cases be asymptomatic, such as atrial fibrillation (AF), incessant 
supraventricular tachycardias (SVT) and non-sustained ventricular tachycardias (NSVT) may, 
however, have important implications for patient outcomes (3-7). Asymptomatic AF can lead to 
stroke, asymptomatic ventricular arrhythmias can lead to sudden cardiac death (SCD) and any 
kind of sustained or repetitive tachyarrhythmias can possibly lead to deterioration of left 
ventricular (LV) function. Interestingly, in the same patient, the same type of arrhythmia can be 
symptomatic in some circumstances but asymptomatic in others (8).  
 
The reasons for this variability in awareness of heart rhythm abnormalities are largely unclear. It 
is also not clear whether asymptomatic arrhythmias should be evaluated and managed 
differently than symptomatic arrhythmias. This is not least because published studies on the 
approach to and therapy of arrhythmias in large part only include symptomatic individuals. 
However, as asymptomatic arrhythmias are neither rare nor in some cases benign, there is a need 
for guidance on this particular topic.  
 
Asymptomatic arrhythmias are frequent in daily practice and may in some cases considered to 
be more benign than symptomatic ones and not in need of treatment. However, it is important 
for clinicians to recognize that this is not always be true and that some asymptomatic arrhythmias 
may require a detailed evaluation and in certain cases, appropriate treatment. Recently there 
has been a rapid increase in the number of medical devices and accessories that can evaluate 
heart rate or even record a rhythm strip that are available directly to consumers. They have the 
potential to increase the diagnostic yield of heart rhythm disturbances and increase the 
prevalence of asymptomatic arrhythmias substantially in the coming years. 
 
Given that the approach to asymptomatic arrhythmias is neither particularly clear or 
straightforward, the European Heart Rhythm Association (EHRA) in collaboration with the Heart 
Failure Association (HFA), the Heart Rhythm Society (HRS), the Asia Pacific (APHRS), the Cardiac 
Arrhythmia Society of Southern Africa (CASSA) and Latin American Heart Rhythm Society 
(LAHRS), convened a Task Force to review the clinical implications of specific types of 
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asymptomatic arrhythmias. The goal was to emphasize evidence-based approaches for risk 
stratification and appropriate pharmacological or non-pharmacological treatments, where 
evidence does indeed exist for asymptomatic arrhythmias.  However, ultimately the decision on 
management must be made by the healthcare provider after discussion with the patient, taking 
in to account individual factors and preferences, along with potential benefits and risks involved. 
 
II. Preamble 
 
Members of the Task Force were advised to perform a detailed literature review, weigh the 
strength of evidence for or against a particular approach, treatment or procedure, and include 
estimates of expected health outcomes where data exist. Patient-specific modifiers, co-
morbidities, and issues of patient preference that might influence the choice of particular tests 
or therapies are considered, as is the need for follow-up and not least cost-effectiveness. With 
regard to issues without evidence other than clinical experience, a consensus was achieved by 
agreement of the expert panel after thorough discussions. This document was prepared by the 
Task Force with representation from EHRA, HFA, HRS, APHRS, CASSA and LAHRS. The document 
was peer-reviewed by official external reviewers representing EHRA, HFA, HRS, APHRS, CASSA 
and LAHRS. 
 
Consensus statements are evidence-based when possible and derived from available published 
data or determined through consensus opinion where data are not available. However, the 
current systems of ranking level of evidence have become complicated such that their practical 
utility can be compromised. Therefore we opted for an easier and a more user-friendly system 
of ranking using ‘coloured hearts’ that should allow physicians to easily assess the current status 
of the evidence and consequent guidance (Table 1). This EHRA grading of consensus statements 
does not have separate definitions of the level of evidence. This categorization, used for 
consensus statements, must not be considered as directly similar to that used for official society 
guideline recommendations, which apply a classification (Class I-III) and level of evidence (A, B 
and C) to recommendations used in official guidelines. 
 
Thus, a green heart indicates a ‘should do this’ consensus statement or indicated treatment or 
procedure that is based on at least one randomized trial, or is supported by strong observational 
evidence that it is beneficial and effective. A yellow heart indicates general agreement and/or 
scientific evidence favouring a ‘may do this’ statement or the usefulness/efficacy of a treatment 
or procedure. A ‘yellow heart’ symbol may be supported by randomized trials based on a small 
number of patients or results which are perhaps not widely applicable. Treatment strategies for 
which there is scientific evidence of potential harm and should not be used (‘do not do this’) are 
indicated by a red heart (Table 1). 
 
Finally, this is a consensus document that includes evidence and expert opinions from several 
countries. The pharmacologic and non-pharmacologic antiarrhythmic approaches discussed may, 
therefore, include drugs that do not have the approval of governmental regulatory agencies in 
all countries. 
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III. Arrhythmias and symptoms 
Arrhythmias may be associated with diverse symptoms, as discussed in the introduction. On the 
other hand, some individuals may be completely asymptomatic from their heart rhythm 
disturbance. It should also be clearly noted that not all individuals that experience palpitations 
are actually having an arrhythmia simultaneously (9). This interesting issue on symptoms or the 
lack of them in arrhythmias is rather poorly understood, but is likely complex and may be 
influenced by a number of recognized and confounding factors. In part this might be because 
many studies suffer from a lack of structured systematic assessments and survey instruments for 
symptoms. In addition there is a lack of good data assessing symptoms and arrhythmia burden. 
Also potential placebo and nocebo effects of therapeutic interventions are not controlled for in 
most studies on symptoms.  
There are could be many possible contributing factors in determining whether arrhythmias might 
cause symptoms or not. The type and origin of the arrhythmia likely play a part in determining 
whether it is symptomatic or not. The presence of various cardiovascular disorders which may 
lead to systolic or diastolic dysfunction likely plays an important role. As such, isolated premature 
beats from both the atria and the ventricles and short bursts of arrhythmias might be less likely 
to produce symptoms than sustained episodes of the same heart rhythm abnormality. There are 
no data to suggest that atrial tachyarrhythmias cause fewer palpitations than ventricular 
tachyarrhythmias although the latter could possibly have a greater effect on blood pressure, 
perhaps leading to dizziness of even syncope. In tachyarrhythmias decreased diastolic filling time 
might contribute to a lowering of blood pressure and symptoms. The hemodynamic effect of a 
heart rhythm disturbance is also likely to be determined by the rate of the arrhythmia, circulating 
blood volume at the time of the arrhythmia, function of the left ventricle, and concurrent co-
morbidities. The faster the ventricular response during the arrhythmia the more likely it is to 
cause symptoms and the lower the left ventricular ejection fraction, the less likely the individual 
is to tolerate a sustained rapid arrhythmia. There are also indications that younger individuals 
may have more symptoms from arrhythmias than those who are older (10). With 
bradyarrhythmias in general it is believed that a sinus or atrioventricular pause of at least 6-7 
seconds is needed to cause symptoms such as syncope (11). 
Many people who have arrhythmias also have structural cardiovascular disorders and are taking 
medications that can affect the ability of the heart to tolerate a heart rhythm disturbance. Such 
medications include beta blockers, calcium channel antagonists and various vasodilators. These 
drugs might accentuate a negative hemodynamic response during a tachyarrhythmia and in turn 
increase the probability of symptoms. They may also have an effect on chronotropic response 
which may also play a role in determining the degree and severity of symptoms. 
 
Sympathetic nervous system afferents are connected to sensory mechanoreceptors which are 
activated by the mechanical stretch resulting from a premature ventricular contraction (12). This 
causes the perception of premature beats by some patients; a similar mechanism may also 
involve vagal afferents, also connected to mechanoreceptors, and this explains the sensation 
referred to the neck region by some patients. The autonomic nervous system modulates cardiac 
activity in a variety of ways and may in some cases have arrhythmogenic effects and facilitate the 
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induction of heart rhythm disturbances (13, 14). Indeed, cardiac sympathetic denervation has 
been used to prevent life threatening arrhythmias (15). The autonomic nervous system tone may 
also affect the rate, persistence and hemodynamic consequences of arrhythmias and via this 
mechanism possibly influence the perception of the individual´s symptoms.  
 
Pain tolerance can vary substantially between patients and the relationship between arrhythmias 
and symptoms also varies greatly between patients. For example, whereas some patients with a 
very high burden of premature ventricular contractions (PVCs) (> 20%) are completely 
asymptomatic, other patients experience uncomfortable symptoms with a single PVC. It is 
sometimes referred to patients with a low threshold for experiencing symptoms with 
arrhythmias as having “cardiac awareness“ (16).  
 
The pathophysiologic basis for this significant variation in threshold for symptoms is not known. 
It is also unknown if genetic influences play a role in whether arrhythmias cause symptoms or 
not, however, cultural variations between populations, ethnicity or educational level certainly all 
play a role in the perception and expression of medical symptoms. There is growing evidence 
demonstrating an association between psychosocial factors and the risk of cardiac arrhythmias 
(17). The type of personality might also have an effect of the individual´s perception of the 
arrhythmia although that relationship has not yet been well defined. 
 
 
IV. Premature atrial contractions and nonsustained atrial tachyarrhythmias.   
Premature atrial contractions (PACs), while common, do not always cause symptoms and many 
patients with PACs may be completely unaware of their occurrence (18). It is less clear, however, 
what proportion of patients who experience PACs have symptoms; what demographic and 
clinical variables predict whether a patient has symptoms at the time of the PACs; and what is 
the link between the number of PACs and the development of associated symptoms?  
 
The occurrence of symptoms in arrhythmias is an issue that has been speculated on in the 
previous chapter and the focus of this section will be to describe the clinical importance of PACs, 
regardless of whether they are symptomatic or asymptomatic. In this regard it is important to 
recognize that most clinical trials, which have studied the clinical impact of atrial premature 
beats, did not categorize atrial PACs on the basis of whether they are symptomatic or not but 
rather their burden over a given period (18-21). It might also be important to note that some 
cohorts may have an unusually heightened awareness of PACs including individuals after AF and 
SVT ablations.  
 
Over the past two decades the rather common belief that PACs are benign and of little clinical 
importance has evolved considerably. Today, it is well recognized that the presence of frequent 
PACs or shorts runs of PACs may be a strong independent predictor of development of atrial 
tachycardia and AF (19-21). However, the impact of having completely asymptomatic PACs is 
currently unknown. 
 
9 
 
There have been some studies that have attempted to evaluate the risk of PACs on outcomes. In 
a study by Binici et al., 48-hour Holter data from the Copenhagen Holter Study, which enrolled 
healthy middle aged men and women, assessed the relationship between PACs and outcomes of 
incident AF, stroke and death (19). In this study 15% of individuals without known cardiovascular 
disease had excessive supraventricular ectopic activity, defined in this case as a 30 PACs burden 
of more than per hour. After a median follow-up time of 6.3 years excessive PACs were associated 
with both the primary endpoint of death or stroke (hazard ratio (HR) 1.64; 95% CI 1.03 to 2.60, 
p<0.036) and admissions for AF (HR 2.78; 95% CI 1.08 to 6.99, p < 0.033) (19).  
 
Also, an increase in the number of PACs has been associated with a greater risk of both death or 
stroke and admissions for AF (19). In the same cohort from Copenhagen but with a longer median 
follow-up of 14.4 years, Larsen and coworkers found that excessive atrial ectopic activity was 
associated with a twofold increase in the adjusted risk of stroke (22).  Interestingly, less than 15% 
of patients with a high number of PACs and stroke had a clinical diagnosis of AF prior to their 
stroke.  Furthermore, the annual stroke risk in patients with excessive atrial ectopic activity in 
combination with a CHA2DS2-VASc score >2 was 2.4% per year which is similar to patients with 
AF and a CHA2DS2-VASc score ≥2, supporting the view that PACs burden might actually be a 
possible surrogate marker for AF. Similar findings were reported by Dewland et al, who examined 
Holter data from 1260 people without previously known AF from the Cardiovascular Health 
Study, and found that a doubling of the hourly PAC count was associated with an increase in AF 
risk (hazard ratio 1.17, 95% CI 1.13 to 1.22) and overall mortality (hazard ratio 1.06, 95% CI 1.03 
to 1.09) (21).  
 
One explanation for this observation could be that the presence of frequent PACs identifies 
patients likely to develop AF, and development of AF leads to an increased risk of stroke and 
death. A second possible mechanism for these observations is that frequent PACs alone may be 
a marker for a subclinical, atrial cardiomyopathy, that might promote both the development of 
AF and increased stroke risk (21, 23, 24). This “atrial cardiomyopathy hypothesis” proposes that 
the development of AF and PACs is an epiphenomenon outside the causal pathway between 
myopathy and stroke. Recent genetic studies showed a connection between mutations in 
sarcomer genes and atrial fibrillation, a link that may be mediated through a subclinical atrial 
cardiomyopathy (25-27). 
 
Many questions remain unanswered concerning this link between PACs, AF, stroke, and 
increased mortality. One is whether treatment of patients with a high burden of PACs with 
antiarrhythmic medications or by means of catheter ablation reduces the risk of developing AF, 
thereby reducing stroke risk and decreasing mortality. Another concern is whether there is a 
clinically important cut-off for what abnormal PAC burden should be. Specific definitions of 
excessive supraventricular ectopic activity are lacking. As this question is unanswered it will also 
be important to do further research to define the day-to-day variability in PAC frequency and 
what the optimal screening test should be. At the present time, a 24-hour Holter monitor is the 
“gold standard” for assessing PAC frequency. According to Gladstone et al, excessive ectopic 
activity was felt to be present when PACs burden was >500 PACs/day are observed on Holter 
monitoring. The probability of AF increased from increased from less than 9% among patients 
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with PACs burden <100/24 h to over 40% in those with a PAC burden of >1500/24 h) (28). In this 
consensus document we have chosen to accept that a high burden of PACs exists when they 
exceed 500 in 24 hours.  
 
Yet another important unresolved question concerns the use of anticoagulation. It stands to 
reason that patients with an increased stroke risk profile who have a certain frequency of PACs 
could benefit from anticoagulation.  However, the benefit/risk of such an approach requires 
testing in clinical trials. Regarding the significance of asymptomatic vs. symptomatic PAC in this 
setting, there is simply lack of data and knowledge. 
 
A summary of studies on PACs and clinical consequences is provided in a table as an online 
supplement.  
 
 
Consensus statement Symbol References 
Patients with a high PAC burden (>500/24 hours) on 
Holter monitor should be considered at increased risk 
for development of AF and be educated on the 
symptoms of AF. They should undergo further 
evaluation for possible AF including more detailed 
monitoring 
 
 
(19-21), 
expert 
consensus 
Comprehensive cardiovascular risk factor modification 
is recommended for patients with a high PAC burden 
including careful control of hypertension, weight loss, 
and screening for sleep apnea. In addition, evaluation 
for structural heart disease should be considered.  
 
 
Expert 
consensus  
When brief episodes of AF, which per se would not be an 
indication for oral anticoagulation (OAC), are observed, 
the burden of PACs (> 500 PACs/24 hour or any episode 
of runs of more than 20 PACs) could add to the decision 
process regarding anticoagulation therapy or not. This 
decision should always be made on an individual basis. 
 
 
Expert 
consensus 
Low to moderate PAC burden without documented AF is 
not an indication for oral anticoagulation  
 
 
 
Expert 
consensus 
 
V. Asymptomatic ventricular pre-excitation  
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The prevalence of ventricular pre-excitation, also termed a delta wave or Wolff Parkinson White 
(WPW) pattern on an ECG, is estimated to be 0.1-0.3% (33, 34). The life-time risk of sudden 
cardiac death (SCD) in symptomatic WPW syndrome has been estimated at 3-4% (35, 36). 
Consequently, there has been a general agreement that symptomatic pre-excitation is a Class I 
indication for an electrophysiology study (EPS) with a view to catheter ablation of the accessory 
pathway.  
 
Individuals with asymptomatic pre-excitation, however, have a lower lifetime risk of SCD and this 
has varied between 0 and 0.6% (35-37). The approach to individuals with asymptomatic pre-
excitation is not as straightforward as in those that are symptomatic and has continued to be a 
hot topic of discussion over the past decades. One of the key issues debated has been whether 
or not to attempt to invasively risk stratify with an EPS and ablate the accessory pathway in those 
at perceived increased risk of sudden cardiac death. Back in 2003, the joint AHA, ACC, ESC 
guidelines did state that the positive predictive value of EPS was too low to justify routine use in 
asymptomatic patients (38). However, this topic continues is far from being resolved. 
 
An initial evaluation of the patient with asymptomatic pre-excitation could include an exercise 
stress test and/or a 24-hour Holter monitor looking for accessory pathway block with increasing 
heart rate and intermittent accessory pathway conduction over the 24 hours. Both are indicative 
of a long effective refractory period (ERP) of the pathway. The individual with intermittent pre-
excitation during sinus rhythm is perceived to be at very low risk for SCD.  
 
On the other hand, high risk features  for increased risk of SCD in patients with ventricular pre-
excitation include a young age (39), inducibility of atrioventricular tachycardia (AVRT) during EPS 
(40), a short antegrade ERP of the accessory pathway (<250 ms) (39-41) and multiple accessory 
pathways (40, 42, 43). It has also been a study suggesting that high adrenergic states, exercise or 
emotion might lead to more rapid conduction over the accessory pathway (24). 
 
A few randomized studies have been performed in attempt to evaluate the risk of sudden death 
in patients with suggested high-risk EPS features. In a rather small study of 73 patients none of 
those who had an ablation suffered AF or VF in follow-up. However, 43% of the control patients 
had AVRT, 14% had AF and there was 1 aborted VF in a 22-year-old male with multiple accessory 
pathways (44). In a similar randomized study of 60 children with high risk EPS features, during 
follow-up 7/27 control patients had AF and there was 1 sudden death in a patient who had first 
presented with AF but whose parents had declined ablation. There were no patients in whom VF 
was the initial presentation (45). In a recent meta-analysis, Obeyesekere et al (46), evaluated 20 
studies including a total of 1869 patients with a mean age of 7 to 43 years. Ten SCDs occurred 
during 11,722 person-years of follow-up. In this analysis, 7 studies originated from Italy and 
reported 9 SCDs. The overall SCD risk was 1.25 per 1000 person-years with children having a 
higher risk (1.93 vs 0.86 per 1000 person-years, P=0.07). There were 156 AVRTs in 9884 person-
years of follow up from 18 studies with a risk of 16 per 1000 person-years follow-up. The authors 
concluded that the low incidence of SCD and AVRT argued against routine EPS in most 
asymptomatic individuals with WPW. 
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Pappone et al (47), recently reported 8-year single centre registry of 2169 patients undergoing 
ablation for ventricular pre-excitation including both symptomatic and asymptomatic patients. 
In the 1001 patients who did not have ablation, VF occurred in 1.5% of patients, virtually 
exclusively (13 of 15) in children (median age, 11 years), and was associated with a shorter 
accessory pathway antegrade ERP and AVRT initiating AF but not with symptoms. In the ablation 
group, ablation was successful in 98.5%, and no patients developed malignant arrhythmias or VF 
over the 8-year follow-up. The authors concluded that the prognosis of the WPW syndrome 
depended on intrinsic electrophysiological properties of the accessory pathway rather than on 
symptoms.   
 
Discussion on this subject has so far failed to reach a clear consensus. It is of importance in this 
discussion to understand that ablation can be performed with exceedingly low risk in the modern 
era and as an example there was only one major complication reported in the above registry in 
2169 patients (29).  
In a systematic review on risk stratification for arrhythmic events in patients with asymptomatic 
pre-excitation for the 2015 ACC/AHA/HRS guidelines on SVT it was concluded that the existing 
evidence suggests risk stratification with an electrophysiological study of patients with 
asymptomatic pre-excitation may be beneficial, along with consideration of accessory-pathway 
ablation in those deemed to be at high risk of future arrhythmias. Given the clear limitations of 
the existing data, well-designed and well-conducted studies are needed (30). 
 
The more recent EHRA guidelines on supraventricular tachycardia suggestions are along similar 
lines (48). EPS for risk stratification may be considered in individuals with asymptomatic pre-
excitation. We would add that this may strongly considered in those that are professional 
athletes or have an occupation risk such as pilots or heavy machinery operators. It may also be 
taken in to account that the presence of a delta wave might exclude individuals, including school 
children, from activities such as sports. Catheter ablation may be considered in those in 
asymptomatic individuals with high risk features, (antegrade ERP of the accessory pathway <240 
ms, inducible AVRT triggering pre-excited AF and multiple accessory pathways). Observation 
without treatment may be reasonable in those with asymptomatic pre-excitation who are low 
risk either due to intermittent delta wave or an electrophysiology study not demonstrating high 
risk features.  
 
 
Consensus statements Symbol References 
Observation may be reasonable in those with 
asymptomatic pre-excitation who are low risk either due to 
intermittent delta wave or an electrophysiology study not 
demonstrating high risk features.  
 
 
(49) 
EPS for risk stratification may be considered in individuals 
with asymptomatic pre-excitation. Catheter ablation may 
be considered in those in asymptomatic individuals with 
high risk features, (antegrade ERP of the accessory pathway 
      
(48) 
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<240 ms, inducible AVRT triggering pre-excited AF and 
multiple accessory pathways).  
 
Catheter ablation should be considered in individuals who 
participate in high intensity or professional sports or 
otherwise have an occupational risk  
 
(48) 
There should be a detailed discussion with the patient and 
his/her family regarding the individual´s personal 
preference and willingness to accept risk, whether from an 
ablation or from untreated asymptomatic WPW. 
 
(36) 
 
 
VI. Atrial fibrillation and flutter 
Asymptomatic AF usually refers to AF that is not associated with symptoms and incidentally 
discovered during routine clinical examination or detected by screening and recorded for ≥30 
seconds via surface ECG method(s) (5, 30, 50) (Table 2). Compared with AF, sometimes termed 
subclinical AF detected via implanted devices (50, 51), AF detected by routine clinical 
examination or an EKG usually implies a higher arrhythmia burden sufficient to be detected using 
single-point or intermittent ECG/Holter/loop recorder recording (51, 52). 
 
The true prevalence of asymptomatic AF is unknown (5, 50). Reported rates vary from 10-40%, 
depending on the risk profile of the evaluated cohort, monitoring intensity and follow-up 
duration, but a greater likelihood of asymptomatic AF has been consistently observed among the 
elderly, males and those with non-paroxysmal AF (2, 53-63). Symptomatic patients (especially 
those managed using a rhythm control strategy) may also have episodes of silent AF, particularly 
after AF catheter ablation (64). Indeed, in patients implanted with a cardiac monitor before 
ablation, a post-ablation setting was the strongest independent predictor of asymptomatic AF 
episodes (65). Since the absence of symptoms may be misleading, a solely symptom-based 
assessment of AF burden or ablation success is usually inaccurate. On the other hand, ablation 
of AF is in many cases used as a treatment for excessive or recurrent symptoms, in which case 
absence of them might in many cases be more than welcome by the patient.  
 
Although the presence of AF symptoms may not be driven only by concomitant cardiac and non-
cardiac conditions, but also by patient-related psychological and somatic factors (66, 67), 
available data suggest that asymptomatic AF could portend a less favorable prognosis, with 
greater morbidity and mortality than symptomatic AF (Table 3), possibly due to a later referral 
for thromboembolic risk stratification and therapeutic intervention. 
 
Management of asymptomatic AF patients generally should be based on the same principles as 
if they were symptomatic (30, 68-70). An integrated approach such as the ABC pathway – Avoid 
14 
 
stroke with Anticoagulation (optimize stroke prevention), Better symptom management 
(patient-centered symptom directed use of rate or rhythm control strategies) and Cardiovascular 
and comorbidity risk factor management (Figure 1) summarizes key components of AF 
management and can help align AF management among healthcare specialties (71). While 
symptom management may not be acutely relevant in asymptomatic individuals with AF, steps 
to try to prevent longstanding AF or decrease the risk of developing tachycardia induced 
cardiomyopathy may be. A trial of rhythm control in asymptomatic persistent AF patients may 
help discern true asymptomatic from symptomatic AF. There are no randomized data on 
treatment effects specifically in asymptomatic AF, but benefits at least similar to those seen in 
symptomatic AF can be assumed (5, 30, 68).  
 
Oral anticoagulant therapy (OAC) using either vitamin K antagonists (VKAs) or non-vitamin K 
antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban or edoxaban 
effectively reduces stroke, systemic embolism and mortality in AF patients at increased risk of 
stroke (72, 73). Compared to VKAs, NOACs exert broadly similar efficacy, but are safer with less 
intracranial bleeding, and more convenient for long-term use (73, 74). The decision to use OAC 
for thromboprophylaxis in AF patients depends on the presence of CHA2DS2-VASc stroke risk 
factors, not arrhythmia-related symptoms (30, 68, 71). In observational studies of asymptomatic 
AF, OAC use versus no therapy has been associated with significant reduction in stroke and 
mortality (75), and residual stroke risk was similar among anticoagulated AF patients and 
matched non-AF controls (76). Good long-term adherence to NOACs (77) may be particularly 
challenging in asymptomatic patients but in a study of screening detected AF, the 5-year 
adherence to OAC was 88% and stroke rates significantly declined (78).  
 
Whether OAC can be stopped after an AF ablation procedure is uncertain, especially since AF 
recurrences are common, and may be asymptomatic. Hence current guidelines recommend 
continuation of OAC in the presence of stroke risk factors, irrespective of the apparent success 
of rhythm control interventions (79). The OCEAN trial is an ongoing multicentre randomized 
controlled trial evaluating two antithrombotic treatment strategies (rivaroxaban vs. aspirin) for 
patients with risk factors for stroke after apparently successful AF ablation (80). 
 
With the greater availability of screening tools, asymptomatic individuals will be increasingly 
diagnosed with paroxysmal AF that would be missed by a routine ECG/Holter recording (5, 50, 
78). The incremental burden of AF, reflected by the clinical types of AF (from paroxysmal, to 
persistent and to permanent AF), has been associated with increasing risk of stroke in post-hoc 
analyses of randomized clinical trials (81-89), AF registries (90-93) and a meta-analysis of 12 
studies (94). Although generally lower in paroxysmal compared to non-paroxysmal AF (Figure 2A-
B), the annual stroke rates among non-anticoagulated patients with paroxysmal AF and ≥1 
CHA2DS2-VASc stroke risk score (81-83) (Figure 2A) is sufficiently high to merit OAC use (30, 68). 
Of note, major bleeding rates among anticoagulated AF patients were broadly similar across AF 
types (84-87, 94) (Figure 2C). Incremental AF burden has been also associated with increased risk 
of tachycardia-induced cardiomyopathy (95, 96), heart failure (58, 97-100), cognitive 
impairment/dementia (101, 102) and mortality (84-87, 94).    
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Asymptomatic AF has been independently associated with greater risk of progression than 
symptomatic arrhythmia (HR 1.6, 95% CI 1.1-2.2) (58). Five and ten years after detection, 
paroxysmal/persistent asymptomatic AF progressed to permanent in 25% and 50% of patients, 
respectively (58, 78). Increasing evidence shows that comprehensive risk factor management 
(e.g., blood pressure lowering (103-105), weight reduction (106-108), glucose control (109), 
treatment of obstructive sleep apnea (110)) and lifestyle modification (e.g., physical exercise and 
cardiorespiratory fitness (111-114), stress management (115, 116)) could decrease the burden of 
AF (117-119). These interventions have not been investigated specifically in asymptomatic AF 
patients, but their benefits would likely be similar to those seen in symptomatic patients (120).   
 
A decrease in AF burden after successful AF catheter ablation could reduce the risk of major AF-
related outcomes including heart failure, stroke and mortality, as suggested by many 
observational studies evaluating mostly highly symptomatic patients (121-135). However, 
observational data have numerous limitations (136), and undertaking AF ablation to abolish the 
need for long-term OAC is presently not recommended (30, 68, 137). The effects of rhythm 
control using AF ablation are currently being explored in several ongoing randomized outcome 
studies (e.g., CABANA [NCT00911508], EAST [NCT01288352], OAT [01959425]. 
 
In the CASTLE-AF randomized study, AF ablation yielded a 47% mortality rate reduction compared 
with conventional rhythm control among symptomatic anticoagulated AF patients with heart 
failure treated with an implantable defibrillator (predominantly middle-aged males with 
moderate left ventricular dysfunction) over a median 3-year follow-up (138).  In the CABANA trial, 
there was no significant difference between catheter ablation compared to medical therapy for 
the primary outcome of composite of death, disabling stroke, serious bleeding, or cardiac arrest, 
although symptoms were improved in the ablation arm (139). 
 
Whether (and how) asymptomatic AF patients would benefit from AF ablation still needs to be 
fully established. Incidental diagnosis of AF may trigger symptoms in susceptible patients as they 
become aware of a heart condition (140), and even failed AF ablation may have a placebo effect 
in such patients (141). A challenge with rhythm control (e.g., using electrical cardioversion) could 
identify apparently asymptomatic patients who had subconsciously adapted to AF by restricting 
their lifestyle or have atypical symptoms (137, 140). In many cases a trial with an anti-arrhythmic 
drug might considered after cardioversion before considering ablation. Whereas these patients 
would likely experience symptomatic improvement after successful AF ablation (141), a failed 
procedure may turn truly asymptomatic patients into symptomatic due to post-procedural atrial 
tachyarrhythmias (such scenario has been reported in 24%-34% of patients) (142, 143). The 
decision to use AF ablation in asymptomatic patients should be a shared informed process that 
considers not only potential benefits (pending further evidence from randomized studies), but 
also the risk of serious procedure-related complications (≤4%) and patient’s values and 
preferences for treatment and outcomes (66) (Figure 1). Notwithstanding that the exact AF 
duration before diagnosis is difficult to establish in asymptomatic patients, consideration of AF 
ablation in such patients may be considered in selected younger patients with paroxysmal or 
persistent (but not long-term persistent) AF (Class IIb, Level of evidence C) (137).  
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As for atrial flutter, a lot of what has been said for AF also applies to this arrhythmia. While the 
risk of thromboembolism is slightly less, the same indications exist for anticoagulation. Atrial 
flutter has however been studied a lot less than AF. Very little is known specifically about 
asymptomatic atrial flutter but treatment options would include initial rate control and 
consideration of cardioversion and/or ablation.   
  
 
Consensus statements Symbol References 
Patients with asymptomatic AF should be anticoagulated, 
according to their calculated risk of stroke, equal to 
patients with overt AF.  
 
(69, 70, 144, 
145) 
Consideration should be given to screening high risk 
individuals e.g. with a CHA2DS2-VASc score > 2 for atrial 
fibrillation. 
 
Expert opinion 
Lifestyle changes should be advised in patients with 
asymptomatic AF, equally to patients with overt AF.   
(69, 70, 144, 
145) 
Cardioversion of persistent AF in asymptomatic patients 
may be advised to differentiate between truly 
asymptomatic patients or those adapted to AF related 
symptoms. 
  
(79, 140) 
Rate control drugs should be prescribed to patients with 
asymptomatic AF with fast AV conduction in order to 
attempt to decrease risk of tachycardia induced 
cardiomyopathy. 
 
(95, 96) 
Ablation might be proposed to selected patients with 
asymptomatic AF, based on patient’s preferences, after 
detailed informed consent. 
     
(79) + expert 
opinion 
 
VII. Atrial high rate episodes  
Atrial high rate episodes (AHRE), also termed subclinical AF, are different from symptomatic or 
asymptomatic AF essentially by the way they are observed. The definition of AHRE varies slightly 
from study to study (6, 144, 146) . In the ASSERT study AHRE was defined as episodes of at least 
5 minutes of atrial rate >180 bpm, detected by the continuous monitoring by cardiac implantable 
electronic devices (CIEDs) (50), while an episode lasting at least 30 seconds on an ECG with 
irregular RR intervals with no discernible, distinct P waves clinically defines AF. This can be either 
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in the presence (overt AF) or absence (asymptomatic AF) of symptoms typically associated with 
AF (i.e. palpitations, shortness of breath, lightheadedness, chest pain, pre-syncope or syncope). 
 
Both AHRE and AF can thus be asymptomatic. Contrary to asymptomatic AF, which can be 
diagnosed in any patients using any kind of diagnostic tool (ECG, Holter monitoring, event 
recorder, implantable loop recorder), AHRE are only diagnosed in patients with CIEDs, and 
various algorithms from different manufacturers can detect these AHRE albeit with variable 
accuracy. Not all implanted devices are able to document AHRE providing intracardiac 
electrograms. The positive predictive value of various atrial rate and episode length was tested 
in the ASSERT population (147). Inappropriate detection of AHRE by counters review only was 
found in 10 to 17% of the > 6 min episodes and 1 to 2 % of the > 24 hours episodes. To what 
extent AHRE can be considered as an early stage of AF is not known. Not all patients with AHRE 
will develop documented AF (148). In the ASSERT study AHRE <24 hours were not associated with 
an increased risk of stroke (149). It needs to be emphasized that there was a temporal 
discordance between AHRE and strokes (146), which is begs the question of whether AHRE are 
causal or perhaps a risk marker of an atrial cardiomyopathy as discussed in the section on PACs. 
It should also be noted that in ASSERT strokes were classifies as ischemic or not but not further 
classified according to subtype. Thus it was not a mechanistic study in the sense that 
cardioembolic strokes were specifically identified.  
 
The prevalence of AHRE in patients with CIEDs has been reported to range between 30 to 60% 
(150). The TRENDS study showed a doubling of risk of thromboembolic events in the presence of 
>5.5 hours AHRE over a 30-day period (151). The ASSERT trial detected AHRE in 10.1% of patients 
over the first 3 months after pacemaker implantation (146). In these patients with AHRE, the risk 
of developing overt AF was 5.6 times higher (95% CI 3.78-8.17, p<0.001) and the embolic risk was 
2.5 times higher (95% CI 1.28-4.85, p=0.007) over a 2.8 years follow-up period. This increased 
stroke risk, stratified according to the CHADS2 score, was however smaller than expected in 
patients with comparable CHADS2 scores with overt AF: an annual stroke risk of 0.6% for AHRE 
vs. 2.8% for AF in CHADS2=1 patients, 1.29% for AHRE vs. 4.0% for AF in CHADS2=2 patients, and 
3.8% for AHRE vs. >5.9% for AF in CHADS2 >3 patients (152). As mentioned previously, there was 
no temporal relationship between stroke and AHRE (153). Longer episodes of AHRE (>24 hours) 
were most associated with increased risk of ischemic stroke or systemic embolism (149).  
 
The only published study assessing anticoagulation of patients diagnosed with AHRE was the 
IMPACT trial, in patients with remote monitoring of ICDs or cardiac resynchronization therapy 
(CRT), without history of stroke or documented AF (154). There was no difference in primary 
outcomes (stroke, systemic embolism, major hemorrhage, mortality) between the intervention 
and control arms when oral anticoagulation was decided according to the CHADS2 score.  So it 
should be emphasized that there is no data yet to indicate whether anticoagulation for short 
AHREs is beneficial. The ARTESIA and NOAH-AFNET 6 trials are currently ongoing to test the effect 
of NOACs in CIED patients with 6 minutes to 24 hours of AHRE and with additional risk factors, 
but without documented AF (155, 156). The results of these studies are expected in 2021. No 
studies to date have suggested any benefit of any rhythm control strategy, including any 
antiarrhythmic drug or ablation, in these asymptomatic patients.  
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Consensus statements Symbol References 
Patients with AHRE have a higher stroke risk compared with 
patients without AHRE.  
(149, 153) 
The benefit of anticoagulating patients with AHRE and 
additional stroke risk factors, but without overt AF, is still 
unclear. Patients with AHRE should be referred for further 
investigations in order to document AF before 
anticoagulation is initiated. The benefit of anticoagulating 
patients with AHRE and additional stroke risk factors, but 
without documented AF, is still unclear. Patients with AHRE 
should be referred for further detailed evaluation unless 
already confirmed by stored electrograms. 
 
(155, 156) + 
Expert 
consensus 
Anticoagulation might be considered on an individual basis 
in those with AHRE and a CHA2DS2-VASc score > 2  
Exepert 
consensus 
AHRE per se do not require antiarrhythmic treatment 
  
Expert 
consensus 
 
VIII. Premature ventricular contractions 
 
Isolated premature ventricular contractions (PVCs) are a normal occurrence in most individuals. 
A few to multiple PVCs can be seen on most 24-hour Holter monitors, including those from 
healthy young individuals (157). These PVCs usually originate from different locations in both 
right and left ventricles. They may result from focal activity or, less likely, be due to a (micro) re-
entrant mechanism. In some individuals, a higher number of PVCs may be present. Frequent PVCs 
may be a marker for underlying abnormal substrate. This may be the result of underlying 
electrical, ischemic or structural alterations, leading to enhanced automaticity (e.g. in chronically 
ischemic tissue), triggered activity (e.g. in long-QT syndrome, or by drugs such as digoxin), or re-
entrant mechanisms (e.g. in post-infarction patients).  
 
Underlying cardiac disease is a prognostically unfavourable marker in asymptomatic patients 
with PVCs and requires a specialist approach to address the potential prognostic impact. PVC 
characteristics, such as a high burden, a more complex presentation (e.g. couplets, triplets or 
non-sustained runs), multifocal origin, and/or increasing PVC frequency with exercise, should all 
alert to potential underlying electrical, ischemic or structural alterations that may be associated 
with the undesired outcome of major ventricular arrhythmias or sudden death (Table 4)  (158, 
159). There is no absolute threshold of the number of PVCs that can be used as a cut-off for 
underlying disease, and hence should trigger further investigations. A study in apparently healthy 
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athletes has shown that in those with >2000 PVC per day, there was a 30% risk of finding 
underlying heart disease (160). Even in the absence of demonstrable underlying disease, a 
moderate to high burden of PVCs are a marker for all-cause and cardiovascular mortality, 
indicating that continued follow-up may be warranted (161). 
 
The morphology of the PVCs can provide important additional information in this diagnostic 
conundrum, since some predilection sites of benign PVC ectopy are well recognised. The most 
prevalent entity in this respect are PVCs originating from the ventricular outflow tract regions, 
showing a clear inferior axis with high voltages in the inferior limb leads (usually with a combined 
amplitude of >4.5 mV of the QRS complexes in leads II, III and aVF). Most frequently, these PVCs 
originate from the right ventricular outflow tract (RVOT), in which case they have a left bundle 
branch morphology in V1 (i.e. a dominant negative QRS complex), with transition between V3 
and V4. Earlier transition, and certainly when V1 shows a right bundle branch morphology, 
suggests a left-sided origin (which may be within the coronary cusps of the aorta, or in the 
endocardium or epicardium of the left ventricular outflow tract (LVOT) (162). These PVCs are 
thought to be the result of triggered activity, i.e. a local cellular cause which in most cases has no 
serious prognostic implications. Therefore, the PVCs are usually strictly unifocal, but slight 
morphological changes are often seen, attributed to different exit points of the ectopic activity. 
Although these RVOT/LVOT arrhythmias usually occur in structurally normal hearts, they may 
rarely be an atypical expression (forme fruste) of arrhythmogenic (right) ventricular 
cardiomyopathy (163). 
  
The absence of imaging abnormalities on an echocardiogram and cardiac MRI can help to rule 
out structural heart disease in such patients. The demonstration of PVCs of differing 
morphologies from the right ventricle (RV) in patients with normal left ventricular (LV) function 
should prompt investigations to rule out arrhythmogenic cardiomyopathy with right ventricular 
dominance or sarcoidosis (164). Similarly, multifocal PVCs of LV origin should trigger 
investigations for non-ischemic cardiomyopathy. 
 
Other less common locations of focal PVC are around the mitral or tricuspid annulus. These PVCs 
are strictly unifocal again but have a superior axis with LBBB or RBBB morphology. Locations away 
from the annulus are usually related to PVC originating from the His-Purkinje system. Finally, 
intramyocardial foci may occur, often related to the papillary muscles or the moderator band 
(165). Some of these foci may present with a pattern of parasystole, indicating poor electrical 
coupling with the surrounding tissue, or generate non-sustained ventricular tachycardia (VT). A 
strict unifocal presentation in the absence of demonstrable structural heart disease points to a 
benign automatic focus in such situations. 
 
Very rarely, otherwise ‘benign’ PVCs may give rise to polymorphic VT or VF due to their short 
coupling interval (159). Short coupled PVCs impinging on the T wave may induce polymorphic 
VT/VF in a setting of ischemia, electrolyte abnormalities, underlying long QT syndrome (LQTS) or 
early repolarization syndrome. This may also rarely occur in a “normal” heart, sometimes called 
‘short-coupled form of torsades de pointes’ (160). Often, such PVCs arise from the Purkinje 
network, but also other foci have been described. In such patients, the malignant electrical 
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presentation mandates aggressive treatment, possibly by ablation. In some, an implantable 
defibrillator may be indicated. 
 
Frequent PVCs (usually defined as >10-15% of the total number of beats per 24 hours) can impair 
LV function (PVC-induced cardiomyopathy) which may be reversible with medical treatment or 
catheter ablation of the extrasystoles and standard therapy for the cardiomyopathy (166, 167). 
However, it is well recognized that not all patients with frequent PVCs will develop LV 
dysfunction. Factors associated with the development of LV dysfunction include: longer PVC QRS 
duration, epicardial PVCs, retrograde atrial activation of PVCs and interpolation of PVCs (168-
170). The PVC burden remains one of the strongest predictors for the development of a PVC-
induced cardiomyopathy, although the burden associated with cardiomyopathy varies between 
studies. Most studies are limited by a strong referral bias in enrolling patients who are 
symptomatic and referred for catheter ablation. The prevalence of LV dysfunction in these 
studies ranged from 7-52% (Table 5).  
 
Asymptomatic patients with frequent PVCs are under represented in these studies. With these 
inherent limitations, there appears to be an increase in risk in the development of PVC-induced 
cardiomyopathy with a PVC burden >10%.  However, PVC-induced cardiomyopathy has been 
reported in individuals with a PVC burden <10% (171, 172).  A recent study measuring subtle 
degrees of left ventricular impairment by using speckle tracking echocardiography (measuring 
left ventricular global longitudinal strain and mechanical dispersion) showed mild impairment of 
myocardial function with a PVC burden > 8%  (173). The wide range reported in studies may be 
partly explained by the single-day Holter monitoring used. A wide daily variation in PVC burden 
is well recognized. Longer monitoring has been shown to double the identification of patients 
with a PVC burden of >10% (174). It can be difficult to determine if the PVCs are the cause or the 
consequence of LV dysfunction. 
 
Two studies have reported the natural history of PVCs. Niwano et al followed 239 consecutive 
patients (mostly asymptomatic) with a PVC burden >1%, with normal baseline LV function, over 
a mean follow-up of 5.6 years (175).  Patients were grouped into those with a high, moderate 
and low PVC burden. Forty six patients had a high PVC burden (>20%), 105 a moderate burden 
(5-20%) and 88 patients had a low PVC burden (1-5%). Thirteen patients (5%) developed LV 
dysfunction (defined as a fall in LVEF by at least 6%) at follow-up. Patients with a high PVC burden 
>20% were more likely to develop LV dysfunction but this change in LVEF occurred very slowly 
over several years with no reported major adverse cardiac events. Dukes et al followed 1139 
elderly (>65 years) patients from the Cardiovascular Health Study who had Holter monitoring and 
were followed up with an echocardiogram five years later and for incident heart failure (176). 
They reported that a PVC burden in the upper quartile (roughly equivalent to >100 PVC/24h) had 
a three-fold increase in the risk of incident heart failure compared to the lowest quartile. The 
population attributable risk of developing heart failure due to PVCs was 8.1%.  
 
The risk of developing a PVC-induced cardiomyopathy rises with increasing PVC burden.  Subtle 
degrees of LV dysfunction can be seen with a PVC burden as low as 8%.  In studies where patients 
were referred for management of PVCs, usually because of symptoms, the predictive PVC burden 
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to cause a PVC-induced cardiomyopathy is >10%, usually >20%. However, the vast majority of 
patients with frequent PVCs >10% will not go on to develop a cardiomyopathy.  Studies from 
Niwano et al and Hasdemir et al., suggest a prevalence of 5-7% for patients with a PVC burden 
>10% (175, 177). Recently, the study by Dukes et al suggested the prevalence of heart failure due 
to PVCs in the elderly population may be higher than previously reported (176).  
 
A proposed scheme to evaluate patients with more than expected PVC is shown in Figure 3. 
Although Dukes et al (176) had described a cut-off of ±100 PVCs/24h, we would suggest setting 
the bar at >500 PVCs to trigger an extensive work-up for underlying disease, given the findings in 
athletes with a 2000 PVCs/24h cut-off (160). Since excluding underlying disease is a cumbersome 
task, there is no defined set of ‘minimal investigations’, but conceptually three axes of evaluation 
need to be explored (imaging, electrical and genetic) based on what may be clinically indicated. 
If the evaluation is negative in an asymptomatic subject, treatment is not required but it seems 
reasonable to perform serial measurements of LV function (yearly) in patients with a PVC burden 
>10%. In patients who develop symptoms, or who have or develop LV dysfunction, medical 
therapy (beta-blockers, calcium blockers with or without anti-arrhythmic drug therapy) and/or 
catheter ablation is indicated. 
 
There are a number of considerations to take into account when deciding whether to treat 
asymptomatic PVCs. In the CAST study, suppression of PVCs by flecainide and encainide after 
myocardial infarction was harmful (178). In cases where patients have frequent PVCs but in the 
background of longstanding remodeled cardiomyopathy (eccentric with thinning) or with large, 
dense STEMI scars, the likelihood of benefit of intervention to improve LV function may be low. 
 
 
 
Consensus statements Symbol References 
Asymptomatic patients with frequent PVCs (>500 per 24 
hours) should be referred to a specialist for further 
evaluation to rule out any underlying structural, ischemic or 
electrical heart disease.  
 
(158, 159) 
Very frequent PVCs (burden>20%) are a marker of all-cause 
and cardiovascular mortality and may justify intensified 
follow-up.  
      
(161) 
PVCs should be treated in patients with suspected PVC-
mediated cardiomyopathy  
Expert 
consensus 
Treatment of patients with asymptomatic PVCs should 
focus on the underlying heart disease in order to improve 
prognosis 
 
Expert 
consensus 
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IX. Ventricular tachycardia 
The definition of NSVT constitutes three or more consecutive ventricular beats at a rate of greater 
than 100 beats/min with a duration of less than 30 seconds. The prevalence of asymptomatic 
NSVT varies from 0.7% (healthy army population) to 10% (in a geriatric population) in patients 
without known heart disease (179-181). On the other hand, it is common in ischemic heart 
disease (30–80% of patients) during long-term ECG monitoring where it is usually asymptomatic 
(182). 
 
Mode of discovery of VT may vary but a 12-lead ECG during arrhythmia should be obtained 
whenever possible. Whereas NSVT may be asymptomatic, sustained VT is much more often 
symptomatic. Slow VT, generally slower than 150 bpm, may however be asymptomatic. When 
lasting for hours/days individuals with slow VT may become symptomatic because of heart failure 
symptoms. 
 
Definitions of different sub-types of VT are summarized in Table 6. Among ventricular 
arrhythmias, two distinct entities require specific mention; bidirectional VT and torsades de 
pointes VT. Bidirectional VT may be asymptomatic. The classic causes are digitalis toxicity or 
channelopathies such as catecholaminergic polymorphic ventricular tachycardia (CPVT) or 
Andersen-Tawil syndrome. Torsades de pointes VT is a type of VT seen exclusively in the setting 
of prolonged QT interval whether it is acquired or congenital.  
 
The goal of evaluation is to try to identify an underlying structural or electrical cardiac disease 
and rule out underlying heart disease, primarily coronary artery disease. Suggested first- and 
second-line evaluations are presented in Table 7. First line investigations include clinical 
evaluation associated with a 12 lead ECG, rhythm monitoring (e.g., Holter monitor), 
echocardiogram, laboratory testing with or without an exercise stress test depending on the 
situation. Second line investigations may include coronary artery angiography, cardiac MRI /CT 
scan to rule out subtle heart disease such as focal cardiomyopathy due to ARVC.  Pharmacological 
testing may be considered in the absence of structural heart disease to evaluate for an inherited 
arrhythmic disorder. This may include ajmaline and if not available flecainide testing to uncover 
Brugada syndrome (183). Other types of pharmacological testing such as epinephrine for 
diagnose LQTS  (184) and isoproterenol for diagnosis of arrhythmias in ARVC have been described 
(185). However, epinephrine and isoproterenol testing for ventricular arrhythmias carry a risk of 
inducing life-threatening ventricular arrhythmias and should only be done by experts under 
optimal circumstances. Genetic testing may also be proposed but should be performed on careful 
clinical indications and preferably in dedicated centres with the experience to interpret results 
and with the ability to provide genetic counselling. The use of signal-averaged ECG has diminished 
but might be considered in special circumstances. 
 
Management of asymptomatic ventricular arrhythmias largely depends on whether structural 
heart disease is present or not. In individuals without structural heart disease, non-sustained and 
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sometimes repetitive idiopathic VT are usually adenosine-sensitive, based on cAMP mediated 
triggered activity, often aggravated by exercise or emotional stress. They mainly originate from 
the right or left ventricular outflow tract, although there are exceptions (186-188). Rarely, 
verapamil-sensitive fascicular VT presents as non-sustained salvos (189-192).  
Prognosis is usually considered benign in those that have no clear heart disease (180, 193), 
although some cases of sudden death have been described, possibly reflecting undetected 
cardiomyopathy or channelopathy (194). However, when asymptomatic, some patients with very 
frequent or incessant NSVT may develop tachycardia-induced cardiomyopathy over time (195). 
Pending symptoms or alteration in ventricular function, observation with no specific therapy is 
perfectly acceptable, although follow-up is mandatory. 
 
Polymorphic NSVT in the absence of heart disease or channelopathy is unusual but requires 
detailed evaluation and in most cases treatment. Malignant polymorphic VT is extremely rare in 
asymptomatic patients, with premature beats triggering polymorphic VT usually arising from the 
right ventricular outflow tract or the Purkinje network (196) with, but not always, short coupling 
intervals (197, 198). In those patients who are asymptomatic, the possibility of quinidine, ablation 
and/or ICD should be discussed with expert electrophysiologists after elimination of reversible 
causes. 
 
In patients with structural heart disease, the presence of asymptomatic arrhythmias usually is a 
more ominous sign.  No antiarrhythmic drugs, except beta-blockers, have been shown to 
decrease in mortality in patients with asymptomatic ventricular arrhythmia and structural heart 
disease. Optimal medical therapy including beta-blocker, ACE inhibitors +/- mineralocorticoid 
receptor antagonist is the first step. After ruling out acute coronary artery stenosis, an ICD is 
indicated for sustained VT without reversible cause with LVEF <35%. However, in case of mild 
structural heart disease with LVEF >40% and well tolerated VT, VT ablation alone has sometimes 
been proposed in ischemic cardiomyopathy (199) and ARVC (200). This, however, needs to be 
determined on a case by case basis.  
 
Table 8 summarizes the treatment for asymptomatic patients with NSVT depending on the 
underlying substrate.  NSVT in an asymptomatic patient with a LVEF > 40% does not usually 
require specific antiarrhythmic therapy, but optimization of the treatment of the underlying 
heart disease (201). However, the prognostic value of an EP study in patients with ischemic 
cardiomyopathy and a LVEF >40% is currently being investigated (202). Despite the high rate of 
sudden death after myocardial infarction among patients with a low ejection fraction, 
implantable cardioverter–defibrillators are generally not indicated until 40 to 90 days after 
myocardial infarction. Surprisingly, the results of the recent VEST trial showed that among 
patients with a recent myocardial infarction and an ejection fraction of 35% or less, the wearable 
cardioverter–defibrillator did not lead to a significantly lower rate of the primary outcome of 
arrhythmic death than control (203). 
 
In patients with left ventricular assist devices, VT is common (204) and may be well-tolerated 
because of the preserved cardiac output from the device. However, VT episodes seem linked to 
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higher mortality (204) and may supress right ventricular function. Therefore, ablation may be 
considered in case of frequent VT episodes (205). 
 
Detailed management of asymptomatic patients with channelopathies is a topic that exceeds the 
purpose of this paper and can be found in dedicated consensus documents (7, 206). A brief 
summary is found in table 9 but a few points warrant mention. When the QTc interval is 
prolonged an assessment of why this has occurred is necessary. Medications are not infrequent 
causes of QT prolongation. If a patient is taking a potential QT prolonging drug it important to 
verify that there has indeed been a further prolongation of the QT interval after the medication 
was started because sometimes it is minimal and drug withdrawal in certain cases could be even 
more damaging. If drug induced QT prolongation and electrolyte disturbance such as 
hypokalemia have been ruled out, consideration should be given to genetic testing for further 
diagnosis.  
 
Asymptomatic non-sustained polymorphic VT in patients with Brugada syndrome or early 
repolarization should be considered a potentially malignant event and be managed accordingly 
(183). Syncope in individuals with Brugada ECG pattern who have not been diagnosed with 
ventricular arrhythmias might be an ominous sign while there are of course many other potential 
reasons for syncope in these patients . Syncope in this population should lead to a very detailed 
evaluation and careful consideration of treatment. However monomorphic NSVT (particularly 
originating from the RVOT) may sometimes be recorded and may not convey an increased risk. 
The management of such patients should, if possible, be discussed with an electrophysiologist, 
who is an expert in Brugada syndrome.  
 
Currently, it is unknown if the few asymptomatic patients with multifocal ectopic Purkinje-related 
PVCs with preserved LV function may benefit from quinidine (207), with SCD only being described 
in patients with altered LVEF. Patients with Andersen-Tawil syndrome are often asymptomatic 
despite presenting with frequent salvos of VT, often bidirectional, and may be incessant (208). 
Rate of malignant events seem to be low on beta-blockers even if they are not directly effective 
in decreasing the VT burden. Flecainide seems effective against VT when combined to beta-
blockers. Catheter ablation does not seem to be an option in these patients (208). 
 
The occurrence of VT in athletes, even when asymptomatic, should lead to a thorough evaluation 
to eliminate the possibility of structural heart disease or the use of illegal and/or performance 
enhancing substances. An echocardiogram, cardiac MRI and exercise test should all be 
considered. Once these possibilities have eliminated, it is well recognized that intense physical 
activity may not only induce VT (209) but also exercise-induced arrhythmogenic RV remodeling 
(210). Sports induced PVCs and VTs were in a recent paper not associated with adverse events in 
athletes without structural heart disease (209). Interruption of physical activity lead to long-term 
resolution of exercise-induced VT, but athletes with persistent VT may be considered candidates 
for ablation to permit return to competitive sports (209).  
 
However, a word of caution is warranted in this situation as individuals with CPVT, who usually 
have structurally normal hearts, may present with exercise induced VT that could be the first sign 
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of high risk for sudden death. Similarly, patients with an asymptomatic myocarditis would not 
always qualify for structural heart disease and they are known to die suddenly during exercise.  
This underscores the importance of a careful evaluation in these individuals. VT associated with 
an isolated sub-epicardial right ventricular outflow tract scar can be found in high-level 
endurance athletes without any evidence of ARVC, and this can be successfully treated by 
ablation with excellent outcomes (210). 
 
While PVCs are common during pregnancy, VT and SCD are exceptionally rare (211). 
Asymptomatic VT in pregnant women with a healthy heart may in most cases be monitored 
without specific therapy. In cases of pregnancy induced cardiomyopathy and asymptomatic VTs 
a temporary use of a life vest might be considered.  
 
In infants without any cardiac abnormality, asymptomatic ventricular arrhythmias are rare and 
often resolve during the first year. Left ventricular dysfunction may be due to asymptomatic VT 
or frequent PVCs and is reversible when the burden is decreased (212). No benefit of any anti-
arrhythmic drug has been shown (213) in this situation in asymptomatic children with a normal 
heart. 
 
Individuals with congenital heart disease may have a variety of arrhythmias, both symptomatic 
and asymptomatic. In patients with tetralogy of Fallot (ToF), the risk related to NSVT is debated 
(214, 215). An EP study may be proposed in case of NSVT (201). An ICD is a Class IIa indication in 
ToF patients presenting with other risk factors, and a Class IIb indication in patients with 
advanced single or systemic right ventricular dysfunction in association with other risk factors, 
according to the 2015 ESC Guidelines on Ventricular Arrhythmias and Prevention of Sudden 
Cardiac Death (7). 
 
NSVT are common in patients undergoing chronic dialysis but mostly unrelated to SCD in this 
population (216, 217); thus, no therapy is recommended. Chemotherapeutic agents (mainly 
anthracyclines, but also other drugs such as melphalan) may acutely promote VT or torsades de 
pointes by different mechanisms, even in those without identifiable underlying heart disease 
(218, 219). Due to the risk of SCD, chemotherapy should be postponed in case of asymptomatic 
VT, until necessary decisions have been made about cessation or continuation of the drug 
together with adapted preventive therapy. 
 
Ventricular arrhythmias are sometimes seen during rhythm monitoring during general 
anesthesia. In this particular situation it is very important to obtain a tracing of the arrhythmia. 
VT under these circumstances should lead to complete evaluation as mentioned above and in 
table 7 should be performed. If normal, there is no need for treatment. 
 
Asymptomatic accelerated idioventricular rhythm may be observed in adults and children 
without structural heart disease (220, 221). It does not convey any increased risk of SCD and 
therefore, no therapy or monitoring is needed.  
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Consensus statements Symbol References 
Patients with asymptomatic NSVT should be referred for 
careful evaluation to detect any underlying structural, 
ischemic or electrical heart disease.  
 
Expert 
consensus 
 
X. Tachycardia induced cardiomyopathy  
Both supraventricular and ventricular arrhythmias can lead to tachycardia-induced 
cardiomyopathy (TICMP) (Table 10). TICMP may be divided into two types: 1) pure, where 
tachycardia is the sole mechanism of worsening of left ventricular (LV) function; and 2) mixed, or 
impure as it was originally termed, where tachycardia worsens a pre-existing cardiomyopathy 
due to a different cause (195). However, the fact that pure TICMP may develop with variable 
incidence and severity in different patients with a similar fast heart rate over a similar duration 
raises the question that a latent cardiomyopathy or an underlying myocardial susceptibility could 
play a role in the development of TICMP. 
 
Several studies in both animal models and in humans have suggested possible pathophysiological 
mechanisms for the development of TICMP (Table 11), although the understanding of this entity 
remains largely unclear. Overlap of the mechanisms leading to TICMP may vary in the different 
types of arrhythmias and their presentations. In patients with AF, the restoration of sinus rhythm 
results in significant improvements in ventricular function, particularly in the absence of 
ventricular fibrosis on cardiac MRI (222). 
 
There are no firm diagnostic criteria for TICMP. In patients presenting with new onset LV 
dysfunction and a chronic or recurrent tachycardia with a heart rate >100 beats per minute, the 
diagnosis of TICMP may be suggested by the elements listed in Table 12 (32). Due to the 
retrospective nature of the diagnosis, it is often difficult to confirm a diagnosis of TICMP which 
can also be made by default after exclusion of other causes of worsening ventricular dysfunction. 
The dilemma in clinical practice is to differentiate TICMP from other forms of dilated 
cardiomyopathy that may be associated with atrial or ventricular arrhythmias.  
 
Assessment of heart failure patients with a suspected tachycardia etiology should include ECG, 
to evaluate the cardiac rhythm and look for signs of myocardial ischemia, while an 
echocardiogram should be conducted to determine LV structure, functional characteristics, and 
to exclude valvular and pericardial abnormalities. A Holter monitor should be considered in the 
event of the tachyarrhythmia being paroxysmal. Evaluation of coronary arteries (by non-invasive 
methods or invasive coronary angiography) is necessary to rule out a potential ischemic etiology 
of the ventricular dysfunction. Cardiac MRI (CMR) imaging can rule out a ventricular scar, shed 
light on myocarditis and some specific etiologies of cardiomyopathy, and myocardial biopsy is 
currently rarely used in this setting (32, 223, 224).  
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Atrial fibrillation, the most prevalent sustained cardiac rhythm disorder, is considered the most 
common cause of TICMP (225, 226) in adults whilst permanent junctional reciprocating 
tachycardia is the most common arrhythmia associated with TICMP in children. The incidence of 
TICMP is variable depending upon the type of tachycardia. In a study of 625 patients referred for 
radiofrequency ablation of various tachyarrhythmias, TICMP was found in 17 (2.7%; 1.3% with 
atrial fibrillation or flutter, 0.5% with other SVT, 1% with PVCs) patients (226). The incidence for 
specific arrhythmias has been described as ranging from 10% in patients with focal atrial 
tachycardia to 25% in patients with permanent atrial flutter and 20–50% in patients with 
paroxysmal AVRT (32, 227, 228). Patients with rapid paroxysmal tachycardia are more likely to 
be symptomatic and be diagnosed sooner than those with slower, but incessant tachycardias. 
Identified predictors of TICMP in patients with frequent supraventricular arrhythmia or PVCs are 
listed in Table 14 (169, 171, 229-231).  
 
TICMP usually resolves with treatment of the arrhythmia. The time course of improvement in 
LVEF is variable due to possible persistent ultrastructural changes. Some patients with TICMP 
may be at increased risk for sudden cardiac death after apparent improvement, which could be 
due to persistent myocardial fibrosis (232). Treatment goals for patients with TICMP are to slow 
the heart rate or reduce extrasystoles, relieve symptoms, prevent hospitalization and improve 
survival. Management of TICMP comprises evidence-based treatment for heart failure (HF) with 
reduced LVEF, including angiotensin converting enzyme inhibitors and beta-blockers and 
aldosterone receptor antagonists, which are fundamentally important in modifying the course of 
systolic HF (29). Diuretics may be used to relieve congestive symptoms.  
 
Treatment of TICMP due to AF involves control of the ventricular response with rate-controlling 
drugs, use of antiarrhythmic drugs, direct-current cardioversion or catheter ablation of the 
tachyarrhythmia (Figure 4), in addition to anticoagulation. AF management also aims to reduce 
symptoms and prevent systemic thromboembolism. Randomized trials comparing outcomes of 
rhythm versus rate control in AF almost two decades ago found no differences in morbidity or 
mortality between these approaches. However, patients were included in these trials because 
the two strategies were considered possible options at baseline, which does not appropriately 
reflect the clinical setting of patients with TICMP where resolution of the arrhythmia is a main 
therapeutic target. In addition, ablation was not widely available at that time.  
 
Rate control therapy commonly includes beta-blockers, and/or digitalis. Non-dihydropyridine 
calcium channel antagonists should be avoided in the context of systolic HF associated with 
TICMP. Amiodarone can be used in patients otherwise refractory to rate control. Amiodarone is 
also the most frequently used drug to control the cardiac rhythm in this setting (30). The decision 
to control the rate or rhythm should be individually tailored (233). Catheter ablation has been 
used in the setting of AF with HF with the consistent demonstration of an improvement in LVEF, 
reduction in symptoms and improvement in quality of life. (234-236) Building on these 
observational series, two recent randomized studies (AATAC and CASTLE-AF) have demonstrated 
superiority in reducing AF burden, reduced hospitalization and reduced mortality with catheter 
ablation in systolic heart failure when compared to drug therapy (138, 237). The CAMERA-MRI 
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study provides further mechanistic insights using cardiac MRI in patients with AF and HF, 
demonstrating the greatest improvement in LV function in individuals with a lower ventricular 
fibrosis burden (238). It is important to recognize that these studies enrolled patients with a 
rather narrow clinical profile and were undertaken in highly specialized units. I.e. they are not 
fully generalizable to other patient populations.  
 
While these studies included “symptomatic” patients, it is important to recognize that in the 
setting of HF, it is not always possible to discern the symptoms related to AF from those related 
to HF. Whether these findings can be extrapolated to the truly “asymptomatic” patient is not 
known. For now, consideration of ablation as a strategy in the asymptomatic patient will need to 
be individualized, taking in to account patient preference, the experience at each centre and the 
disease state. Atrial flutter is more difficult to rate control compared to AF. Given the high success 
rate and low risk of complications with catheter ablation of typical right sided atrial flutter, 
ablation to eliminate atrial flutter is recommended when TICMP is suspected (31). For atypical 
atrial flutter this should be decided on an individual basis as indicated before.  
 
A radical form of rate control strategy is atrioventricular (AV) nodal ablation with implantation of 
a permanent pacemaker programmed to VVIR mode (30). This procedure may be associated with 
a better prognosis and seems more relevant for older patients with significant co-morbidities 
(239). Since continuous right ventricular pacing may be deleterious for LV systolic function due 
to LV dyssynchrony, simultaneous cardiac resynchronization therapy (CRT) as de novo pacing. His 
bundle pacing holds promise as an attractive mode to achieve more physiological pacing (240). 
AV nodal ablation is associated with a substantial reduction in all-cause mortality, cardiovascular 
mortality and rates of hospitalization for HF, with improvements in New York Heart Association 
functional class when compared with medical therapy in AF patients receiving CRT in 
observational and randomized studies (241, 242) and this may apply to patients with AF-related 
TICMP. AV nodal ablation might be a feasible early strategy in individuals with TICMP and a 
preexisting pacemaker or CRT device.  
 
PVCs leading to TICMP can either be suppressed by use of antiarrhythmic agents or eliminated 
by use of radiofrequency ablation (Figure 4) as discussed in section VI. A therapeutic trial with 
drugs for at least three months or catheter ablation may be considered for patients with 
presumed PVC-induced TICMP. Beta-blockers, amiodarone and dofetilide (in some countries) can 
all suppress PVCs and can be safely used in patients with LV dysfunction (243-245). Flecainide is 
not recommended in this setting. Catheter ablation is a very efficient and recognized option for 
these patients as the safety and efficacy profiles of the procedure have improved. Several studies 
have documented an improvement in LVEF following PVC ablation in nearly all patients along 
with significant reductions in LV end-diastolic dimensions, mitral regurgitation and New York 
Heart Association functional class (246-248). Short-term ablation success rates of between 70% 
and 90% have been reported (249, 250). Early improvement in LVEF after ablation may help to 
predict complete recovery of LV systolic function (250). Although these strategies with 
antiarrhythmic drugs or ablation differ in their ability to suppress PVCs and in LV dysfunction 
improvement, their effect has not translated into improvement in survival so far. 
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There is no data to support safe withdrawal standard heart failure treatment after improvement 
of left ventricular function. 
 
 
Consensus statements Symbol References 
Other cause of cardiomyopathy (myocardial infarction, 
valve disease, hypertension, alcohol or drug use, stress 
etc.) should be eliminated before considering a diagnosis 
of tachycardia induced cardiomyopathy (TICMP) 
 
(195, 223) 
Management of TICMP should involve drug treatment 
for heart failure, rate control in the case of atrial 
fibrillation when rhythm control not feasible and rhythm 
control for the specific arrhythmia (including AF) causing 
TICMP 
 
(32, 195, 222, 
223) 
Ablation may be preferred for rhythm control of 
persistent or repetitive atrial or ventricular arrhythmia, 
even when asymptomatic, in suspected TICMP cases. 
 
(32, 223) 
 
 
XI. Asymptomatic bradycardia 
 
Asymptomatic bradyarrhythmias, including sinus node dysfunction (SND) and atrioventricular 
(AV) conduction disturbances can be noted during routine evaluation or diagnostic workup of an 
individual who is symptomatic from another cardiac or extracardiac disorder. In this situation it 
is important to differentiate between those who are truly asymptomatic from individuals who, 
frequently due to slow progression of the disease, have yet to notice subtle symptoms. For 
further evaluation, a 24 to 48 hour Holter may give additional information. Also, functional tests 
such as a treadmill or a stationary bicycle can be useful to evaluate whether there is an 
appropriate chronotropic response to exercise and to potentially unmask symptoms. A 
pacemaker is only indicated for symptomatic bradycardia with a very few exceptions. 
 
Very few studies have examined the prognostic value of asymptomatic bradycardia in the general 
population. From an outpatient database, the long-term outcome of 470 patients  > 60 years in 
age with asymptomatic sinus bradycardia (i.e. heart rate < 55 bpm) was compared with that of 
2090 patients without bradycardia (251). During a mean follow-up of 7.2 years, patients with 
bradycardia had a very low rate of subsequent pacemaker implantation (<1% per year) and 
asymptomatic bradycardia had no adverse impact on all-cause mortality and may even have been 
protective. Molgard et al. (252), performed repeated 24-hour Holter monitoring in 183 healthy 
individuals aged 40-85 years. Pauses were documented in 16-31% of the recordings. Subjects 
with pauses had a significantly lower average heart rate. Pauses >1.5 sec occurred in 6-6.5% of 
the subjects whereas pauses ≥2 sec were rare in non-athletes, occurring in 1-1.6% of the subjects. 
The majority of the pauses were due to SND, mainly sinus arrest in older patients. In another 
study of 26 elderly (>70 years) subjects studied by Holter monitoring, the longest sinus pauses 
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were observed during sleep and ranged from 0.8 to 2.5 sec, and were not associated with 
symptoms (253).  
 
Certain bradyarrhythmias (first degree and second degree Mobitz type I AV block) are common 
in younger individuals in a resting state and also in competitive athletes.  They are generally 
deemed to be of little concern in the absence of underlying structural heart disease. Recently, a 
systematic review of the published literature on cardiac pauses in competitive athletes was 
performed (254). The study population comprised 194 individuals with cardiac pauses of 1.35–
3.0 seconds. When specific records for pause durations were provided, 106 athletes had pauses 
≤3 seconds, of whom 92 were asymptomatic and 14 had pauses >3 seconds, of whom 9 were 
asymptomatic. Few subjects were deemed to require medical intervention at the time of 
diagnosis and there were no deaths during 7.5±5.1 years of follow-up. It was concluded that the 
accepted 3 second pause threshold does not adequately discriminate between potentially 
asymptomatic and symptomatic competitive athletes, and in isolation should not be used as a 
determining factor to exclude potential competitors. Further, the three second pause threshold 
does not appear to warrant either exercise restriction or early therapeutic intervention.  
 
With the increasing availability of prolonged monitoring techniques, it is not unusual to 
document even long asymptomatic pauses in patients that have experienced syncope. In the 
absence of a cause–effect relationship, the meaning of asymptomatic pauses in patients with a 
diagnosis of unexplained syncope is uncertain. This issue is of practical importance, since a good 
correlation with the index syncope would allow the use of non-syncopal documented events as 
surrogate endpoints. Few studies have found a good intra-patient correlation between non-
syncopal and syncopal episodes. In a study of 60 patients with unexplained syncope, 
asymptomatic severe bradyarrhythmias, including > 5 second pauses, > 10 second 3° AV block 
and heart rate < 30 bpm for > 10 seconds while awake, was observed in 7 patients and led to 
pacemaker implantation (255).  
 
In a sub-study of the ISSUE2 study, Moya et al. (256), correlated the ECG findings saved by an 
implantable loop recorder (ILR) during non-syncopal episodes, either pre-syncope or nonspecific 
symptoms, with those recorded during syncope in order to evaluate their possible role in 
predicting the mechanism of syncope. Nine patients had an automatic activation of their ILR, i.e. 
were asymptomatic, and 9 had nonspecific symptoms. In these 18 patients, the documentation 
of an arrhythmia showed a high probability as a diagnostic finding, making it unnecessary to wait 
for syncope to be documented and allowing, in those cases in which it is considered indicated, to 
initiate therapy earlier.  
 
There are limited data regarding the beneficial effect of pacing in patients with a history of 
syncope but with asymptomatic intermittent bradycardia without extended pauses during 
monitoring. The length of the documented pause is of importance for the decision to implant a 
pacemaker. While ventricular pauses of 3 seconds or longer are uncommon, these pauses usually 
do not cause symptoms, and the presence of these pauses does not necessarily portend a poor 
prognosis or the need for pacing in asymptomatic patients (257). The position of the patients 
when the pause occurs may have an impact on how long a pause is needed to impact 
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consciousness. In patients with a clinical diagnosis of neurocardiogenic syncope and 
asymptomatic pause(s) >6 seconds, there is weak evidence that cardiac pacing may be effective 
and useful for the reduction of syncopal recurrences. The rationale behind the 6 second cut-off 
value includes data showing that loss of consciousness may take up to 7 seconds in case of 
circulatory arrest (11).  
 
In patients presenting with asymptomatic intermittent night time bradycardia (sinus bradycardia 
or AV block), sleep apnea should be considered as a possible cause. It was estimated that 
episodes of heart block occur in approximately 20% of patients with severe sleep apnea, i.e. 
apnea–hypopnea index >60/h) and approximately 7.5% of an unselected group of patients with 
obstructive sleep apnea (258). Rapid eye movement sleep and excessive vagal activation due to 
hypoxia and apnea seem to be important mechanisms leading to bradycardia. Treatment with 
continuous positive airway pressure should be attempted first, since it has been shown to lead 
to a complete prevention of heart block in 80–90% of these patients. 
 
It is not uncommon to record asymptomatic episodes of AV block on prolonged ECG monitoring. 
Asymptomatic bradycardia is not uncommon and interpretation of this should be made in the 
clinical context of the patient. In healthy subjects pauses >2.5 seconds are infrequent but this 
alone does not necessarily define a clinical disorder. Asymptomatic bradycardia is common in 
athletes and the accepted 3 second pause threshold neither warrants exercise restriction or early 
therapeutic intervention (254). Pauses in AF patients between 3 to 5 seconds are frequently seen 
and may be a normal occurrence.  Treatment is not required except in case of symptoms. 
In the case of AV block, it is crucial to distinguish nodal from infra-nodal localizations, the latter 
usually requiring pacemaker implantation. Key for this distinction are the type of AV block, the 
presence or absence of wide QRS complexes and the heart rate changes at the time of AV block. 
Progressive PR prolongation prior to the nonconducted P wave is typical for type I second degree 
AV block. True type II second degree AV block should be recognized through careful analyses of 
the tracings since it denotes a severe disease of the conduction system and may in most cases 
warrant pacemaker implantation. In the case of a single asymptomatic nonconducted P wave a 
decision should be made on a case by case basis. When wide QRS complexes are present, an 
infra-Hisian localization should be considered, even in case of type I second degree AV block and 
may prompt an electrophysiological study. Slowing of the heart rate at the time of AV block is 
diagnostic of AV nodal localization while block in the His-Purkinje system can be tachycardia-
dependent. In addition, careful analysis of the tracings should rule out concealed His bundle 
extrasystoles which may mimic both types I and/or II AV block. Exercise testing may be 
beneficial to identify infra-Hisian block. There is some data indicating that pacing of type 1 
second-degree AV block may be of benefit in selected asymptomatic elderly individuals (259). 
However, this area clearly needs further investigation before any conclusive recommendations 
can be made.  
 
There is a consensus that third degree AV block in the absence of correctable causes and Type 
II second degree AV block (Mobitz II) should be treated with a pacemaker even in the absence 
of symptoms given the potential severity of these findings (260).  
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Consensus statements Symbol References 
In individuals with syncope the presence of 
asymptomatic severe bradycardia or pauses >6 seconds 
should be considered a diagnostic finding and lead to 
treatment. 
 
(261) 
Completely asymptomatic bradycardia does in itself not 
require treatment. 
 
 
(260, 262) 
 
XII. Patient perspective  
 
As clearly stated in the document, cardiac arrhythmias can be episodic or persistent, and in many 
individuals they may be asymptomatic.  However, the absence of symptoms in arrhythmic 
conditions does not necessarily mean that the patient does not require treatment or is not at risk 
of adverse outcomes.  Indeed, asymptomatic cardiac arrhythmias may be associated with worse 
outcomes as often the detection of the arrhythmia is made following a first presentation to 
hospital for a serious arrhythmia-related event, such as stroke (in AF), cardiac arrest (e.g., 
ventricular arrhythmias), or TICMP. 
 
Even in the absence of symptoms, once an arrhythmia has been diagnosed, patients may still 
experience significant distress and worries about the arrhythmia. This may extend to the 
therapeutic options with their possible side-effects (e.g., bleeding with oral anticoagulant 
therapy, side effects of AADs and other medications, ICD implantation etc.) and the potential 
consequences of the arrhythmia (death, stroke, heart failure, etc.) (263-266). Absence of 
symptoms may also affect the choices that the individual makes in regard to treatment 
pathway/options, as the patient may perceive that they have ‘less severe’ disease due to lack of 
symptoms. This may in turn lessen their appreciation of the seriousness of the consequences of 
the arrhythmia and the necessity of treatment.  Lack of symptoms may also affect the treatment 
options offered to patients, for example in AF rhythm-control strategies (cardioversion and 
ablation) are usually targeted at symptomatic patients, as the goal of such therapy is symptom 
reduction or resolution. Lifestyle restrictions and/or modifications frequently accompany a 
cardiac arrhythmia diagnosis, either directly as result of the arrhythmia (e.g., inherited 
arrhythmia disorders, WPW, etc.) or of the treatment options required to manage the arrhythmia 
(e.g., ICD).  In those with an inherited arrhythmia or WPW, the diagnosis typically occurs when 
the patient is relatively young and otherwise fit and well and such a diagnosis may permanently 
alter the quality of life and may lead to profound psychological distress (264, 267).   
 
It is essential that, regardless of the type of arrhythmia, patients are fully informed about the 
trajectory of their condition; the available treatment options (risks and benefits and side effects, 
particularly for ICD implantation); lifestyle changes that are required to modify their risk factors 
and reduce their risk of adverse outcomes; likelihood of treatment success and what can be 
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achieved so that people can form realistic expectations of treatment and make informed 
decisions about the treatment options that are right for them (48, 66, 144, 268, 269). Patient 
education is a fundamental part of arrhythmia management (66, 268, 270), irrespective of 
symptoms.  It is also crucial to acknowledge patients’ concerns and assess and monitor the 
psychological impact of the arrhythmia and its treatment on the patient and their family, and to 
formulate a plan to manage distress (66), since psychological distress can influence patient 
adherence and persistence with treatment and drastically reduces patients’ quality of life and 
that of their families (271-276), irrespective of the presence or absence of symptoms. 
 
A 2015 EHRA consensus document summarizes the current literature on cardiac arrhythmias and 
patients values and preferences for their management (66) and also provides important topics 
for physician-patient discussions concerning their arrhythmia and disease course, treatment 
options and goals, and outcomes, and helpful resources to elicit these conversations. 
 
Shared decision-making should be the approach adopted to accomplish this target; incorporating 
both the patient and the physician/healthcare professional, mutual shared information, bilateral 
(patient and physician) deliberation about preferences, options, and reaching a shared treatment 
decision (including no treatment as a possibility). 
 
Consensus statements Symbol References 
Education is an essential component of the 
management of cardiac arrhythmias to enable patients 
(and their carers/family members) to understand their 
condition, the available treatments, disease trajectory, 
and possible outcomes, regardless of symptoms. 
 
 
(66) 
All patients should receive individually tailored disease- 
and treatment-specific information from their 
healthcare team which is reiterated over time and 
when new management strategies are discussed. 
 
 
(66) 
Patients’ preferences for treatment should be 
discussed, documented, and incorporated into 
management decisions. 
 
 
 
(66) 
 
XIII. Areas of future concern  
 
During the process of writing this consensus document on asymptomatic arrhythmias it became 
increasingly evident that there is a significant paucity of data from studies that are adequately 
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represented by asymptomatic patients. Many of the sections in this consensus document have 
included data which have been extrapolated from studies on predominantly symptomatic 
arrhythmias and some even from highly selected subgroups. Therefore the formation of 
recommendations for asymptomatic arrhythmias has in some cases been a somewhat complex 
task. Also, asymptomatic arrhythmias vary considerably regarding their risk to cause adverse 
effects and the need to intervene. Nevertheless, in instances where no treatment might lead to 
potentially severe consequences, such as stroke in AF and subsequent cardiac arrest in 
individuals with sustained VT, it would irresponsible to withhold treatment despite lack of 
symptoms from the arrhythmia.  
 
The reasons for the lack of symptoms in some individuals are still poorly understood. While 
treatments aiming to decrease the perception of benign symptomatic arrhythmias are common, 
technology aiming to enhance patients and care providers awareness of serious arrhythmias 
could also be useful. Such alerts as an example already exist in some CIEDs and serve the purpose 
to notify a patient having an asymptomatic but potentially malignant ventricular arrhythmia. 
 
The consumerization of medical devices will likely lead to a significant increase the diagnostic 
yield and observed prevalence of asymptomatic tachycardia, bradycardia, and probably atrial 
fibrillation in the very near future. A number of companies including Fitbit, Garmin, Apple, and 
Samsung, all have devices on the market with heart rate alert features. Smartwatch and fitness 
band wearable consumer electronics can passively measure pulse rate from the wrist using 
photoplethysmography. Identification of pulse irregularity or variability from these data has the 
potential to identify AF. The rapidly expanding consumer base of these devices will allow for 
detection of undiagnosed AF in a completely new manner. Other companies, including AliveCor 
and Withings also have ECG watches or watch accessories. Apple has an irregular rhythm 
notification now that is being prospectively evaluated in a clinical trial which will include more 
than 400,000 individuals (277). While the opportunities created by these possibilities are exciting, 
they will undoubtedly emphasize the need for clearer guidance on how and when to intervene 
in those with asymptomatic heart rhythm abnormalities.   
 
Although this document focuses mostly on asymptomatic arrhythmias, patients should be 
warned of symptoms they might develop or have been dismissed in the past. In particular the 
features of syncope and near syncope. Important medical mis-assessments have included 
diagnosis of anxiety and/or hypoglycemia in patients that have arrhythmias. 
 
Finally, in many different asymptomatic heart rhythm irregularities, the distinction between 
significant and non significant burden of the arrhythmia remains unclear. Furthermore, some 
arrhythmias could have been diagnosed during either direct or indirect screening, or because of 
the increased use of detection devices, such as smartphones apps, or special watches. These 
individuals may represent a group having an even lower burden of arrhythmias, and to the same 
extent as subclinical AF discovered through CIEDs, using continuous monitoring, may represent 
potentially less harmful arrhythmias. Further studies are needed to evaluate the seriousness and 
net clinical benefit of treatment in these patients.  
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Table 2. Detection of asymptomatic AF: Clinical setting, screening methods and screening 
tools. 
 
Detection of asymptomatic AF 
Clinically detected Screen-detected 
C
lin
ic
al
 s
e
tt
in
g 
 Clinical visit for other reasons 
(e.g., acute illness, 
cardiovascular risk factor 
management, regular follow-
up visit) 
 Preparation for surgery or an 
invasive intervention 
 Self-detected by home BP 
measurement or pulse 
checking S
cr
ee
n
in
g 
m
et
h
o
d
s 
 Pulse check 
 Opportunistic screening 
 Screening of a pre-defined 
population at increased risk 
of AF (e.g., the elderly, post-
stroke patients) 
 Community screening of all 
subjects living in a specific 
area 
 Systematic screening of the 
population 
Sc
re
en
in
g 
to
o
ls
 
 Clinical (patient history, risk 
scores, pulse checking, BP 
measurement) 
 Single-lead ECG (electrical 
stick, monitor, monitoring 
patch, watch-like recorder) 
 Multi-lead ECG (Holter 
monitoring, Multielectrode 
belt)  
 Loop recoder 
Detection of subclinical AF and AHREs 
C
lin
ic
al
 s
e
tt
in
g 
 Patients implanted with a 
CIED (e.g., anti-bradycardia 
PM, ICD) for other reasons 
 Patients implanted with a 
cardiac monitoring device 
due to symptoms suggestive 
of an arrhythmia, post 
syncope, etc.  
Sc
re
en
in
g 
m
et
h
o
d
s 
 Opportunistic screening in 
patients implanted with a 
CIED for other reasons 
 Targeted screening for AF in 
patients at increased risk of 
AF (e.g., post an embolic 
stroke - ESUS) 
Sc
re
en
in
g 
to
o
ls
 
 Pacemaker 
 ICD 
 Implantable loop monitor 
 Telemetry of an ICM 
 
AF: Atrial Fibrillation; BP: Blood pressure; ECG: Electrocardiography; AHRE: Atrial High Rate Episodes; CIED: Cardiac 
Implantable Electronic Device); PM: Pacemaker; ICD: Implantable Cardioverter Defibrillator; ESUS: Embolic Stroke 
of Undetermined Etiology; ICM: Implantable Cardiac Monitor. 
Asymptomatic AF refers to AF diagnosed by conventional means while subclinical AF is used to denote AF 
diagnosed by implantable devises only. 
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Table 3. Baseline characteristics and outcomes in asymptomatic AF patients: post-hoc analyses of RCTs and observational studies. 
 
 
 
 
 
Study/post-hoc 
analysis 
(publication 
date) 
AFFIRM   
(2005)(56
) 
 
RACE 
(2014)(59) 
 
Olmsted 
County  
(2011)(6
3) 
Belgrade AF 
(2013)(58) 
UK-CPRD* 
(2014)(75) 
EORP-AF 
Pilot 
(2015)(61)  
ORBIT-AF 
(2016)(60)  
Olmsted 
County 
(2016)(2) 
Fushimi AF 
Registry 
(2017)(62) 
Study type RCT, 
post-hoc  
RCT, post-
hoc  
Retro-
spective 
Single-
centre, first-
onset AF 
Administrative 
dataset 
International 
registry 
International 
registry 
Retrospective Community-
based survey 
Cohort size (n) 4060 522 4,618 1,100 30,260 3,119 10,087 476 3,749 
Asymptomatic 
AF 
12% 30% 25% 13.3% 18.4%* 39.7% 38.2% 33.8% 52.6% 
Follow-up 
(mean) 
3.5 y 2.3±0.6 y  9.9±6.1 
years 
≤3 years 1 year Median 1.8 y Median 6.0 y 3.0 y 
Baseline characteristics of patients with asymptomatic AF  
Male 
predominance 
         
Older age          
Non-
paroxysmal AF 
         
Slower heart 
rate 
         
More 
comorbidity 
         
Higher stroke 
risk 
         
Treatment differences  
Rate control          
Rhythm control          
OAC          
Outcomes (asymptomatic AF vs comparator**)  
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AF progression    1.6 (1.1-2.2)      
Stroke  6% vs 7%  2.1 (1.2-3.9) 19.4 vs 8.4* 23.8% vs 
29.7% 
1.13 (0.87-
1.46) 
2.6 (1.1-6.1) 1.28 (0.82-
2.01) 
Mortality 1.07 
(0.79-
1.46) 
5% vs 8%  0.8 (0.4-1.9) 40.1 vs 20.9* 9.4% vs 4.2% 1.00 (0.86-
1.16) 
4.0 (2.3-6.9) 1.71 (1.31-
2.29) 
MI     9.0 vs 6.5*  1.05 (0.72-
1.53) 
  
Heart failure  0% vs 6%  0.7 (0.4-1.1)     0.96 (0.65-
1.44) 
Dementia          
Major bleeding  4% vs 4%   7.7 vs 4.0*  1.21 (1.02-
1.45) 
 1.18 (0.74-
1.90) 
 
        More common in asymptomatic AF;        No difference;         Less common in asymptomatic AF;        Greater risk of worse prognosis;;         Not reported.  
*Patients incidentally diagnosed with AF were compared to matched non-AF controls; otherwise, the comparator was symptomatic AF. *Outcomes presented as crude incidence 
rates per 1000 patient-years; otherwise, Hazard Ratios (95% Confidence Interval) or event rate, where reported. RCT: Randomized Clinical Trial; AFFIRM: Atrial Fibrillation Follow-
up Investigation of Rhythm Management; RACE: Rate Control versus Electrical cardioversion for persistent atrial  
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Table 4: Factors that may point to worse prognosis in patients with PVCs and that need a 
thorough investigation to rule out underlying structural, ischemic or electrical disease. The 
additional evaluations should be individually tailored, in analogy with the flowchart in Figure 
3. 
 
 Underlying structural, ischemic or electrical disease 
 More than 2000 PVC / 24 hours 
 Complex PVCs (couplets, triplets, non-sustained VT) 
 Increasing number of morphologies 
 Increasing number PVCs with exercise 
 Non-outflow tract PVC (usually monomorphic or only slightly divergent morphologies) 
 Short coupling interval of the PVCs (“R-on-T”) 
 PVCs with broader QRS complexes (more frequently related to cardiomyopathy) 
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Table 5: Summary of studies relating PVC burden with LV dysfunction 
 
 
 No of 
patients 
with PVCs 
No of patients 
(asymptomatic) 
No of patients 
with LV 
dysfunction 
(definition) 
PVC burden 
(no LV 
dysfunction) 
PVC burden 
(LV 
dysfunction) 
PVC burden 
predictive for LV 
dysfunction 
 
Lowest PVC 
burden with LV 
dysfunction 
Baman et 
al.(231) 
(2010) 
174 17 57 (LVEF<50%) 13+/-12% 33+/-13% 24% (sensitivity 
79%, specificity 
78%) 
10% 
Hasdemir 
et al.(177) 
(2011) 
249 26 17 (LVEF<50%) 8.1+/-7.4 29+/-9.2% 16% (sensitivity 
100%, specificity 
87%) 
_ 
Munoz et 
al. (171) 
(2011) 
70 - 17 (LVEF<50%) 16.7+/-13.7 29.3+/-14.6% 15/17 had PVC 
burden >10% 
2/17 had PVC 
burden <10% 
Ban et al. 
(230) 
(2013) 
127 7 28 (LVEF<50%) 22+/10% 31+/-11% 26% (sensitivity 
70%, specificity 
78%) 
- 
Blaye-
Felice at 
el.(172) 
(2016) 
186 - 96 (LVEF<50%) 17+/-12% 26+/-12% - 10/96 had PVC 
burden <10% 
Lie et 
al.(278) 
(2017) 
52 - 15 (GLS worse 
than -18%) 
5% 22% >8% - 
Park et al 
(279) 
(2017) 
180 36 52 (LVEF 
<50%) 
28+/-11.6% 30.7+/-10% 
 
26% (sensitivity 
63%, specificity 
87%)  
- 
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Table 6. Definitions of different sub-types of ventricular tachycardia 
 
Type of ventricular arrhythmia Definition 
Non-sustained VT  Three or more consecutive ventricular beats 
terminating spontaneously in less than 30 seconds 
with a cycle length of <600 ms (>100 bpm) 
  -Non-sustained monomorphic VT NSVT with a single QRS morphology 
  -Non-sustained polymorphic VT NSVT with a changing QRS morphology and a cycle 
length between 600 and 180 ms 
Monomorphic sustained VT VT greater than 30 seconds in duration or 
terminated by external intervention with a stable 
QRS morphology 
Bidirectional VT VT with a beat to beat alternans in the frontal plane 
axis often associated with digitalis toxicity or 
channelopathies such as CPVT or Andersen-Tawil 
syndrome 
Torsades de pointes Polymorphic VT characterized by twisting of the 
peaks of the QRS complexes around the isoelectric 
line often associated with long QT. 
-Typical: initiation following a long/short/long 
coupling interval 
-Atypical: short coupled variant initiated by R on T 
PVCs 
Accelerated idioventricular rhythm Ventricular rhythm slower than <100 bpm 
 
Ms: milliseconds; NSVT: non-sustained ventricular tachycardia; VT: ventricular tachycardia 
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Table 7. Evaluation of patients with asymptomatic sustained or non-sustained VT 
 
First line evaluation 
History Prior cardiovascular disease, Hypertension, Syncope or near-
syncope, Relation of VT to exercise… 
Family history SCD, inherited arrhythmia syndromes, coronary artery disease, 
cardiomyopathy? 
Medications QT prolonging drugs, sodium channel blockers, drug interactions? 
Physical examination Sign of structural heart disease or heart failure 
Twelve-lead ECG Q-waves, ischaemic changes, prolonged or fractionated QRS, QT 
prolongation or shortening, J point elevation and coved-type ST 
elevation V1–V3, early repolarization, epsilon waves, or T-wave 
inversion anteriorly, laterally or inferiorly 
Prolonged rhythm 
monitoring (Holter-
ECG) 
Day/night/effort appearance 
Frequency and duration of episodes 
Echocardiography Sign of structural heart disease 
Laboratory  Serum electrolytes, renal function, thyroid function and BNP 
Stress test Suspicion of coronary artery disease, exercise-related symptoms, 
borderline QT interval. VT provocation by exertion 
 
Second line evaluation 
Non-invasive 
evaluation of 
coronary artery 
Low suspicion of coronary artery disease 
Coronary 
arteriography 
High suspicion of coronary artery disease 
Cardiac MRI Suspicion of structural heart disease such as ARVC, HCM, cardiac 
sarcoidosis, congenital abnormalities 
Electrophysiological 
study 
In case of NSVT, coronary artery disease and moderate LV 
dysfunction (EF<40%), syncope 
Pharmacological 
testing 
- Ajmaline test 
- Flecainide test 
To unmask suspected Brugada syndrome  
Genetic Testing In case of suspicion of inherited arrhythmic disorders 
 
ARVC: arrhythmogenic right ventricular cardiomyopathy; HCM: hypertrophic cardiomyopathy; 
LV: left ventricular; NSVT: non-sustained ventricular tachycardia; SCD: sudden cardiac death; VT: 
ventricular tachycardia 
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Table 8. Treatment of asymptomatic patients with NSVT depending on underlying structural 
heart disease 
 
Clinical Setting Risk of 
sudden 
cardiac 
death 
Prognostic 
evaluation 
Treatment References 
Acute STEMI<48 
hours 
Not 
increased 
Coronary artery 
disease 
- Optimal medical 
therapy including 
beta-blocker 
- Revascularization 
 
Acute STEMI >48 
hours 
Increased 
risk 
Waiting for 6 
weeks post MI 
 
- Optimal medical 
therapy (ACE 
inhibitors, beta-
blockers and 
mineralocorticoid 
receptor antagonist) 
(280, 281) 
Previous MI, LVEF 
36-40% 
Increased 
risk 
PVS ACEI, beta-blocker 
+/- ICD depending 
on PVS 
(282, 283) 
Previous MI, 
LVEF≤35% 
Increased 
risk 
Careful evaluation 
of LVEF 
ACE, beta-blocker, 
mineralocorticoid 
receptor antagonist 
ICD 
(283, 284) 
Non-ischemic 
dilated CMP 
Uncertain Uncertain 
- Cardiac MRI to 
identify an 
underlying 
substrate 
- PVS is 
controversial 
- Optimal medical 
therapy (ACE 
inhibitors, Beta-
blockers and 
mineralocorticoid 
receptor antagonist) 
- ICD if LVEF<30% 
See relevant 
guidelines 
(7, 201, 285, 
286) 
Myocarditis 
sequelae 
Uncertain Uncertain 
-Cardiac MRI to 
identify an 
underlying 
substrate 
- Beta-blockers 
- ICD when 
LVEF<30% and 
acute phase of 
myocarditis ruled 
out 
(7) 
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-PVS may be 
considered 
-Exercise test 
 
Mitral valve 
prolapse CMP 
Possible 
increased 
risk 
Uncertain 
-Cardiac MRI to 
identify myocardial 
scar 
- Benefits of beta-
blocker unclear 
- ICD may be 
discussed in 
selected cases 
(287-289) 
HCM Increased 
risk 
 
NSVT 
defined as 
≥3 
consecutive 
ventricular 
beats at 
≥120 BPM 
lasting <30 
seconds 
Determine other 
criteria for risk 
stratification: 
TTE, Cardiac MRI, 
Stress test or stress 
echo, genetic 
testing 
ICD or nothing 
depending on risk 
stratification (see 
relevant guidelines) 
(290) 
ARVC Probably 
increased 
risk 
- Evaluation of RV 
and LV function 
-  Consider PVS 
- Beta-blocker 
- ICD should be 
discussed according 
to risk stratification 
- Consider catheter 
ablation in carefully 
selected cases 
(200, 291) 
Left ventricular 
non- compaction 
Uncertain None Same criteria than 
for non-ischemic  
dilated CMP 
(7) 
Cardiac 
Amyloidosis 
Uncertain None -Specific treatment 
of amyloidosis 
-No ICD indication 
for 
 primary prevention 
at present time 
(7) 
 
ACE: angiotensin converting enzyme, Acute STEMI: acute ST elevation myocardial infarction, 
ARVC: Arrhythmogenic right ventricular cardiomyopathy, BPM: beats per minute, CMP: 
cardiomyopathy, HCM: hypertrophic cardiomyopathy, ICD: Implantable cardioverter 
defibrillator, MI: myocardial infarction, LVEF: left ventricular ejection fraction, PVS: programmed 
ventricular stimulation, RV: right ventricle 
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Table 9: Treatment of patients with asymptomatic ventricular arrhythmias in the setting of 
channelopathies 
 
 
CPVT: catecholaminergic polymorphic ventricular tachycardia, ICD: Implantable cardioverter 
defibrillator, MEPPC: multifocal ectopic Purkinje-related premature contractions, PVC: 
premature ventricular contractions, VT: ventricular tachycardia 
 
 
 
 
 
 
 
 
 
 
Asymptomatic ventricular arrhythmia Treatment options 
Monomorphic sustained or non-sustained VT If evaluation for structural heart disease 
with echo, cardiac MRI is normal, no 
therapy. Need follow up and monitoring 
of LV function 
Polymorphic VT Culprit PVC ablation 
Discuss ICD and/or quinidine 
MEPPC Discuss quinidine 
Andersen Tawil Beta-blockers 
+/- flecainide or calcium channel blocker 
CPVT on beta-blockers Ascertain the intake of beta-blocker 
Add flecainide and/or left cardiac 
sympathetic denervation 
Discuss ICD 
Long QT syndrome Correction of hypokalemia if present 
Careful consideration of QT prolonging 
drug withdrawal. Consider genetic 
testing and beta-blockers if no reversible 
cause found 
 
Brugada syndrome and early repolarization 
syndrome 
Quinidine 
Discuss ICD with expert in Brugada 
syndrome 
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Table 10. Types of arrhythmias that can lead to tachycardia-mediated cardiomyopathy. 
Supraventricular tachycardia 
 Atrial fibrillation 
 Atrial flutter 
 Atrial tachycardia 
 Permanent junctional reciprocating tachycardia 
 AV nodal re-entrant tachycardia 
 AV re-entrant tachycardia 
 Inappropriate sinus tachycardia (rare) 
Ventricular tachycardia 
 Any type of ventricular tachycardia 
Premature contractions 
 High burden of premature ventricular contractions 
Pacing 
 High-rate atrial pacing 
 Persistent rapid ventricular pacing  
 Permanent pacing with right ventricular stimulation 
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Table 11. Possible pathophysiological mechanisms leading to tachycardia induced 
cardiomyopathy 
 Alteration in systolic function: left ventricular dilation with lack of hypertrophy 
 Alteration in diastolic function: incomplete relaxation (diastolic contracture) 
 Alteration in diastolic function: decreased filling time  
 Loss of atrial contraction for atrial arrhythmias  
 Atrial contractile dysfunction in sinus rhythm for atrial arrhythmias with atrial 
cardiomyopathy 
 Cardiac desynchronization at the atrioventricular level for ventricular arrhythmias 
 Cardiac desynchronization at the interventricular level for ventricular arrhythmias or 
atrial arrhythmias with functional bundle branch block. 
 Depletion of myocardial phosphates energy stores 
 Decreased myocardial blood flow 
 Oxidative stress  
 Decreased response to beta-adrenergic stimulation 
 Activation of the renin–angiotensin–aldosterone  
 Mitral regurgitation developing with dilated cardiomyopathy 
 Changes in right ventricular myocardial geometry (hypertrophy) 
 Left ventricular hypertrophic response during recovery from TICMP  
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Table 12. Elements for the diagnosis of tachycardia induced cardiomyopathy 
1. No other cause of cardiomyopathy (myocardial infarction, valve disease, hypertension, 
alcohol or drug use, stress etc.) 
2. Absence of left ventricular hypertrophy 
3. No major increase in LV dimensions (LV end-diastolic dimension <6.5 cm) 
4. Recovery of LV function after control of tachycardia (by rate control, cardioversion or 
radiofrequency ablation) within a time frame of one to six months. 
5. Rapid decline in LVEF following recurrence of tachycardia in a patient with recovered LV 
function after previous control of tachycardia. 
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Table 13. Possible predictors or elements associated with development of TICMP 
TICMP induced by supraventricular tachycardia 
 Younger age 
 Male sex 
 Slower tachycardia (with less symptoms before heart failure is present) 
 Incessant arrhythmia 
 Irregularity of R-R interval  
 Lack of symptoms in AF of atrial flutter 
 
TCIMP induced by premature ventricular contractions (PVC) 
 PVC burden (from >10,000/ 24h to >24% of total beats; threshold may be lower for 
right as compared to left ventricular PVCs) 
 Wider PVCs 
 PVCs of epicardial origin 
 Presence of interpolated PVCs  
 Presence of retrograde P waves  
 PVCs that are asymptomatic 
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Figures 
 
 
 
Figure 1: The Atrial fibrillation Better Care (ABC)pathway depicting some key components of AF 
management 
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Figures 2a-b. Annual stroke rates (y-axis) among non-anticoagulated patients with paroxysmal, 
persistent and permanent AF (x-axis) and ≥1 CHA2DS2-VASc stroke risk factor. 
 
Figure 2a  
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Figure 2b 
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Figure 2c.  Major bleeding rates (y-axis) among anticoagulated AF patients were broadly similar 
across AF types (x-axis) 
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Figure 3.  
Evaluation of patients with > 500 premature ventricular contractions per 24 hours. There is no 
defined set of ”minimal investigations”, but conceptually three axes of evaluation need to be 
explored (imaging, electrical and genetic) and investigations considered on an a case to case 
basis. 
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Figure 4. Potential management strategy for patients with tachycardia induced 
cardiomyopathy (TICMP) 
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Supplemental table.  
 
 
Studies on PACs and their association with AF and stroke (for supplement)  
Study Study 
population 
Cardiac 
Monitoring 
 
Design 
(primary 
endpoint) 
N  
(% 
Females; 
follow-
up time) 
Age ESVEA 
Definition 
Main finding 
Bicini et al. 
(2010)  
Normal 
middle aged 
persons 
without 
known 
cardiovascular 
disease 
48-h Holter 
on inclusion 
Prospective 
(association 
between 
ESVEA and 
strokes or 
death) 
678 
subjects 
(41.4%;  
6.3 
years) 
Median 
age 64.5 
(SD 6.8) 
ESVEA: 
More than 
30 APCs 
per hour 
or any 20 
APCs in 
run 
 
 
99/579 
 
ESVEA associated with: 
 Stroke/death: HR 1.64 
(CI 1.03-2.60; p<0.036) 
Admission for AF:  HR 
2.78 (1.08-6.99; 
p<0.033)  
Also as a continuous 
variable SVEC was 
associated with 
stroke/death or AF 
admissions 
Larsen et 
al. 
(2015) 
 
 
Normal 
middle aged 
persons 
without 
known 
cardiovascular 
disease 
48-h Holter 
on inclusion 
Prospective 
(association 
between 
ESVEA and 
strokes or 
death) 
678 
subjects 
(41.4%;  
6.3 
years) 
Median 
age 64.5 
(SD 6.8) 
ESVEA: 
More than 
30 APCs 
per hour 
or any 20 
APCs in 
run 
 
 
After adjusting for 
baseline risk factors 
ESVEA was associated 
with ischemic stroke 
when censoring 
subjects at time of AF 
(HR 1.96; p < 0.05).  
 
85% of individuals with 
ESVEA who develop 
stroke had their stroke 
before atrial fibrillation. 
 
The annual stroke risk 
in patients with ESVEA 
and a CHA2DS2-VASc 
score >2 was 2.4% per 
year which is similar to 
comparable patients 
with AF  
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All new 
patients seen 
at the 
cardiovascular 
clinic 
24-h Holter Retrospective 
registry 
(incident AF) 
2.589 
subjects 
(44.5%;  
 
Mean 
571.4 
(606.4) 
days 
Median age 
54.2 (15.5) 
Frequent 
APCs were 
defined as 
more than 
102 
beats/day 
(the top 
quartile) 
The incidence of new AF was 2.7 
for patients with less than 102 
APCs/day versus 37.7 per 1000 
patient years for patients with 
frequent APCs. 
 
Adjusted Hazard Ratios for  
frequent APCs compared with 
nonfrequent APCs was 9.49  
(p<0.001). 
Patients with 
cryptogenic 
stroke 
24-h in 
hospital 
Holter 
monitoring 
 
Subsequent 
monitoring 
with 
implantable 
loop 
recorder 
(Reveal XT) 
Incident AF 
during FU 
70 
patients 
(39%;  
536 days) 
58.8±13.4 N.A. 12/70 (7.6%) had AF during FU 
 
Median number of APCs was 1.5 
per hour. 
 
Patients with AF had a median of 
22.8 APCs/h versus 1.2 APCs/h in 
non-AF patients (p<0.0001). 
 
Patients in the upper quartile of 
APCs (>14.1/h) and short runs 
(>0.2/h) had a relative risk of 4.0 
(CI 1.1–14.6; P=0.04) and 6.9 (CI 
1.8–26.7; P=0.005) for future AF, 
respectively 
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Gladstone 
et al. 
(2015) 
Patients with 
cryptogenic 
stroke  
(EMBRACE 
Trial) 
24-hour 
baseline 
Holter 
followed by 
a 30-day 
external-
belt event 
recorder 
Incident AF 
during follow 
up 
237 
patients 
without 
AF history 
and 
normal 
sinus 
rhythm 
on 
admission 
N.A. Number of 
APCs 
(continuous 
variable) 
Baseline Holter median 
APC count/24 h was 629 
among those who 
subsequently had AF 
detected versus 45 in 
those without AF. 
APC count was the only 
significant predictor of 
AF. 
 
The probability of AF 
increased from <9% 
among patients with 
<100 APCs/24 h to 9% to 
24% in those with 100 to 
499 APCs/24 h, 25% to 
37% with 500 to 999 
APCs/24 h, 37% to 40% 
with 1000 to 1499 
APCs/24 h, and 40% 
beyond 1500 APCs/24 h 
Vinther et 
al. 
(2016) 
Patients with 
ischaemic 
stroke 
48-h in-
hospital 
continuous 
cardiac 
telemetry 
Prospective 
(combined 
primary 
endpoint 
was a 
recurrent 
ischemic 
stroke/ 
TIA or death) 
565 
patients 
in SR 
(44.6%; 
4 years) 
Patients 
without 
runs of 
APCs: 
mean age 
69.9 years 
(13.5) 
 
Patients 
with runs: 
75.4 y 
Runs of 
APCs: 
3 or more 
PACs 
lasting less 
than 30 
seconds 
during 48 
hours 
telemetry. 
 
28% had runs of APCs 
 
Runs of APCs were 
associated with more 
severe stroke 
 
In the patients with 
mild-to-moderate 
strokes, runs of APCs 
were independently 
associated with 
an increased risk of a 
recurrent ischemic 
stroke/TIA or 
death. 
Vinther 
et al. 
(2017) 
Patients with 
ischaemic 
stroke 
24-h Holter 
on 
inclusion 
and 48-h 
Holter at 6 
– and 12 
month FU 
Prospective 
(association 
between 
ESVEA and 
recurrent 
stroke or 
death) 
256 
patients 
(45%; 32 
months) 
 
89 had AF 
and 167 
were in SR 
at inclusion 
Mean 
age 73 
(12.6) 
More than 14 
APCs per hour or 
3 or more runs 
of premature 
atrial complexes 
per 24 hours 
31 of 167 patients in SR 
had ESVEA (18.6%). 
 
ESVEA associated with 
stroke/death: HR 2.55 
(CI 1.41-4.63); p= 0.002 
Alhede et 
al. 
(2017) 
Patients with 
paroxysmal 
AF 
participating 
in the 
MANTRA 
PAF trial 
At baseline 
and 3, 6, 
12, 18 and 
24 months 
follow-up 
patients 
underwent 
Prospective 
RCT 
(MANTRA 
PAF trial) 
260 
patients 
randomised 
to either 
AAD (N = 
132) or CA 
(N = 128). 
 Patients were 
allocated 
according to 
low, moderate 
and high APC 
burden defined 
as 0–25 
AAD was superior to CA 
in suppressing APC 
burden after treatment 
of paroxysmal AF.  
After CA APC burden 
increased immediately 
post-procedural 
78 
 
7-day 
Holter 
monitoring 
to assess 
SVEC and 
AF burden 
APCs/day, 25–
100 APCs/day 
and >100 
APCs/day in 
correspondence 
to a report from 
Varounis et al.  
followed by a decrease 
whereas after AAD an 
early decrease was 
observed. Lower SVEC 
burden was highly 
associated with lower 
AF burden during 
follow-up especially 
after CA. 
 
Abbreviations: 
APCs: Atrial Premature Contractions; ESVEA: excessive supraventricular ectopic activity; AF: 
Atrial Fibrillation; SR: Sinus rhythm; N.A.: data not available. AA: antiarrhythmic medication; CA: 
Catheter ablation. 
 
